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In Finland the economic evaluation of the vaccination programme has been part of the 
decision-making process since 2001. After 2003, five vaccinations have been considered for 
the Finnish national immunisation programme (NVP) and for which an economic evaluation 
has been conducted. This study presents the materials, methods, and results of the economic 
evaluations of 7-valent pneumococcal conjugate vaccination (PCV7) and influenza 
vaccination programmes and human papillomavirus (HPV)-associated cost of illness study, 
all of which were used in the vaccine adoption decision-making process in Finland in 2001–
2011.  
When a new vaccine is considered for inclusion into the NVP in Finland the expected public 
health benefit, the safety of the vaccine for an individual, the safety of the vaccination 
programme at the population level, and the cost-effectiveness of the vaccination programme 
are evaluated. An economic evaluation is needed to support the decision-making process. The 
decision-makers have not specified an explicit range of cost-effectiveness threshold values 
below which an intervention would automatically be accepted and lead to funding.  
In the first economic evaluation of the infant PCV7 vaccination programme (excluding 
indirect herd effects) the cost per QALY gained was EUR 54 600. The decision-makers 
concluded that the programme was not cost-effective. In the economic re-evaluation, 
including the indirect herd effects of the vaccination programme in older age groups reduced 
the cost per QALY gained to EUR 20 600. Thus, infant pneumococcal vaccinations were 
accepted into NVP in 2010.  
The influenza vaccination programme of healthy children was found to yield cost savings 
from the health care provider perspective even though the indirect herd effects and influenza-
associated deaths were excluded. The vaccination programme was estimated to save annually 
EUR 7.6 per vaccinated child aged 0.5–4 years when the assumed vaccine efficacy was 60%. 
Thus vaccinations of all children aged 6–36 months with influenza vaccine were accepted 
into the NVP in 2007.  
In Finland, there is a considerable annual disease burden of HPV-related genital disease in 
the female population. Most of it is detected by the 446 000 annual screening tests, 55% of 
which are carried out as opportunistic tests. It is noteworthy that the opportunistic tests 
account for 71% of the total of EUR 22.4 million screening costs. Considering all tests taken 
both within and outside the organised programme, the 5-year coverage of Pap testing in 
Finland was 87% among women aged 25–69 years. Further diagnostics, management and 
treatment of HPV-related genital disease resulted in an additional cost of EUR 22.3 million, 
of which the costs of less severe HPV-related disease manifestations were EUR 15.5 million.  
At present, 60% of Pap tests detecting most of the cervical cancer and intraepithelial 
neoplasia cases in Finland are carried out outside the organised programme. Thus, the 
successful reduction in the cervical cancer incidence and mortality is due to tests taken both 
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within and outside organised screening. Opportunistic Pap testing both substitutes and 
overlaps with the tests taken within the organised programme. Overlapping tests stem from 
the lack of coordination between organised and opportunistic Pap testing and result in 
overmanagement of reversible lesions. In order to be able to coordinate organised and 
opportunistic Pap testing, it is essential to establish a nationwide Pap test register. Likewise, 
it is important not to lose the high coverage when trying to achieve reductions in overlapping 
Pap testing. Furthermore, such a register is necessary for the effective and cost-effective 
secondary prevention of cervical cancer, which will be needed in both unvaccinated and 
vaccinated populations.  
The estimates produced in the disease burden and costs of HPV-related genital disease in 
women and the overall coverage, frequency and costs of Pap testing were further used as data 
in the HPV transmission and progression model and in the economic evaluations of the HPV 
vaccination programme and screening of cervical cancer. Vaccinations of all girls aged 11–13 
years with HPV vaccine was estimated to yield cost-savings and was accepted into the NVP 
in 2013.  
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1 Introduction  
1.1 National vaccination programme in Finland  
The aim of the national vaccination programme (NVP) is to provide the best possible 
protection for the Finnish population against vaccine-preventable diseases. The NVP started 
to take shape in the late 1950s when well-baby clinics covered almost the whole country. In 
Finland, all childhood vaccinations are provided in well-baby clinics or school health care 
clinics, both of which are part of public primary health care. Vaccinations are free-of-charge 
and voluntary.  
In 2006 all children were offered protection against eight diseases: diphtheria, tetanus, 
pertussis, polio, severe infections caused by Haemophilus influenzae type b, measles, mumps, 
and rubella (1). In addition, vaccination against tuberculosis, hepatitis A and B, seasonal 
influenza and tick-borne encephalitis were offered to special risk groups. After 2006, three 
new vaccines were introduced into the NVP. Vaccinations against infections caused by 
rotavirus and pneumococcus were introduced in 2009 and 2010, respectively. Vaccination 
against infections caused by human papillomavirus has been provided for all girls since 2013. 
In addition, eligibility criteria for seasonal influenza vaccine were extended in 2007 to 
include all children aged 6–36 months. 
1.2 Decision-making  
The Ministry of Social Affairs and Health (MSAH) is authorised by law to make decisions 
concerning the NVP after consultation with the National Institute for Health and Welfare 
(THL). THL is the expert institution on vaccinations in Finland, which guides, develops and 
supports the NVP. THL 1) supports decision-making concerning the NVP, 2) co-ordinates the 
work done at the THL-appointed vaccine-specific working group and at the National 
Advisory Committee on Vaccinations (KRAR), 3) studies and evaluates the vaccine-
preventable burden of disease, 4) monitors and assesses the population-level effects of 
vaccinations (burden of disease, immunology, safety, cost-effectiveness) by means of the 
national vaccination register and other health care registers, 5) produces and disseminates 
information on vaccinations, and collaborates with the public health centres responsible for 
carrying out vaccinations, and 6) procures and distributes the vaccines included in the 
national vaccination programme. 
THL appoints the National Advisory Committee on Vaccinations (KRAR) that oversees the 
international development of vaccines and vaccination programmes, supports THL and 
MSAH in the development of NVP and the preparation of decisions, and gives THL general 
guidance and recommendations on vaccinations both within and outside the NVP. 
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MSAH is the decision-making authority on the NVP in Finland and is responsible for 
combating communicable diseases and widespread diseases in the Finnish population. MSAH 
appoints an Advisory Board on Communicable Diseases that is the national expert body for 
combating communicable diseases, thus 1) monitoring the general development of 
communicable diseases, 2) supporting the preventive health services and 3) making 
statements on the NVP.  
Figure 1 illustrates the current decision-making process for adopting a new vaccine into the 
NVP. When the need for an evaluation is acknowledged, for example, because a new vaccine 
is coming into the market or there is a potential change in the benefit-risk ratio of the 
vaccination programme (e.g. change in disease incidence, vaccine effectiveness or safety), a 
vaccine-specific working group is established by THL. The working group is composed of 
national experts on vaccines and vaccinations, infectious diseases, epidemiology and health 
economics. It may also consult individual experts or pharmaceutical companies if needed. 
The working group carefully evaluates the potential vaccination programme according to four 
criteria given by KRAR: 1) expected public health benefit, 2) safety of vaccine for an 
individual, 3) safety of the vaccination programme at the population level, 4) cost-
effectiveness.  
To be able to determine the expected public health benefit, the working group needs data on 
the burden of disease in Finland, the efficacy of the vaccine in the target group and the effect 
of vaccinations on the whole population. The incidence of the infectious disease, mortality, 
life years lost and the use of health care services are estimated from health care registers. 
Also, health-related quality-of-life losses due to the disease are estimated. To evaluate the 
direct and indirect effect of vaccinations on the population, a dynamic transmission model of 
the disease is required (2). The effectiveness among the vaccinated and unvaccinated 
(potential indirect effects) population is evaluated separately (3). In some cases, the expected 
public health benefit can be considerable only in a sub-population with a higher risk of 
disease than the general population. For example, individuals with certain medical conditions 
have a higher risk of complications associated with influenza and people living in some 
geographical areas are more likely to contract tick-borne encephalitis than the population in 
general.  
The safety of the vaccine for an individual and the safety of the vaccination programme at the 
population level are evaluated. The population-level safety of a vaccination programme may 
be jeopardized through indirect effects of vaccinations (e.g. shift of disease to older age 
groups or replacement of the eliminated microbe by another capable of causing disease)(4-8). 
These potential indirect effects in the population can be investigated using dynamic 
transmission models (3, 9).  
For a new vaccine to be accepted into the NVP it must have been assessed to be cost-
effective. Yet, the decision-makers have not specified an explicit range of threshold values in 
Finland for a cost per QALY gained what should be considered cost-effective. This may 
jeopardize the transparency of decision-making. The cost-effectiveness analyses are done in 
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the Department of Health Protection at THL. In order to maintain the independence of the 
analyses, they have been financed by the State Budget. The cost-effectiveness analyses can 
be done from the health care provider perspective and from the societal perspective, if 
deemed helpful to the decision-making. The effectiveness of the vaccination programme is 
measured both in life years gained (LYGs) and quality-adjusted life years (QALYs) gained.  
A Working Group recommendation is presented to the National Advisory Committee on 
Vaccination (KRAR) summing up the expert opinion. THL gives its recommendation to 
MSAH after hearing the expert opinion of the Working Group and KRAR. The decision on 
the introduction of a new vaccine into the NVP is finally made by MSAH when it has 
received the THL recommendation and consulted its Advisory Board on Communicable 
Diseases. The decision on funding is made by the Finnish Parliament. After the decision-




Figure 1. Decision-making process for adopting a new vaccine into the national vaccination 
programme (adapted from (10)). 
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1.3 Resources, costs, and funding of the national vaccination 
programme  
The vaccines of the NVP are purchased centrally and funded by the government budget. Due 
to the introduction of new vaccines, government budget appropriations for vaccine purchases 
have increased from EUR 5.3 million in 2001 to EUR 10.6 million in 2007 and further to 
EUR 22.9 million in 2014. These figures do not include supplemental funds for pandemic flu 
vaccines.  
The budget appropriation is used for the 1) purchase, storage and distribution of vaccines, 2) 
guidance on vaccine usage, 3) investigation of the epidemiological and immunological 
impact, coverage and safety of vaccinations as well as the development of their surveillance 
systems, 4) management of obligatory storing system, 4) the payment of the Finnish Co-
operative for Pharmaceutical Injury Indemnities, and 5) procurement costs.  
All vaccines for the NVP are purchased according to an open EU-tender procedure. The 
storage and distribution of vaccines is outsourced to a wholesale distributor of pharmaceutical 
products. Vaccines are distributed to hospital pharmacies and pharmaceutical centres, which 
reallocate the vaccines to the municipal health care centres where the vaccinations are carried 
out.  
When the introduction of a new vaccine into the NVP is considered, THL researchers and 
experts compile the data that the vaccine-specific working group needs to be able to form the 
required expert opinion. Approximately 4 full-time equivalent employees (equivalent to 
EUR 240 000) are allocated annually to the evaluation of vaccination programmes at THL. 
The work of the members of vaccine-specific working groups that are not THL employees is 
not included in this figure. Each member is compensated for a meeting by a nominal fee 
totalling from EUR 1200 to EUR 26 000 per working group.  
In addition to the cost of vaccines there are also other costs related to the introduction of a 
new vaccine. These costs include the administrative costs of vaccinating, e.g. supplies and 
time nurses spend on the routine activities of vaccinating, as well as on information 
dissemination. THL provides information on the new vaccine programme to health care 
workers and to target groups. It is essential to assess the feasibility and acceptability among 
health care workers and those to be vaccinated to achieve a good vaccination coverage.  
Approximately 4 full-time equivalent employees (equivalent to EUR 240 000) are allocated 
annually to the implementation of vaccination programmes at THL. In addition, wider media 
campaigns have been launched for seasonal influenza and HPV vaccination programmes. The 
annual costs of the materials (e. g. posters, handouts, and brochures) for the seasonal 
influenza vaccination campaign have been on average EUR 27 000. In 2015–2016 the costs 
of materials were considerably higher (EUR 60 000) after the live attenuated influenza 
vaccine (LAIV) was implemented for two-year-olds for the first time. Half of the costs were 
accounted for by a survey of public health nurses and parental knowledge and attitudes 
towards intranasal LAIV. In addition to these marginal costs, there are fixed costs that are 
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covered by the already existing public health care system (well-baby clinics and school health 
care clinics provided by local municipalities) that carries out all vaccinations in the NVP in 
Finland.  
According to the Communicable Diseases Act (1986/583, revision 2010/1244), THL shall 
monitor the efficiency and effects of the vaccines used for the prevention of communicable 
diseases. The surveillance of infectious diseases is conducted through health care registers 
held by THL. The National Infectious Diseases Register is based on the notifications of cases 
of generally hazardous or notifiable communicable diseases. In 2016 eight full-time 
equivalent employees (equivalent to EUR 480 000) are allocated annually to maintain the 
National Infectious Diseases Register at THL. The Care Register for Health Care (former 
Hospital Discharge Register) contains data on inpatient care and secondary outpatient care. 
The National Vaccination Register is used in the follow-up of vaccination coverage, safety, 
and effectiveness. The Vaccine Adverse Effects Register is a spontaneous vaccine safety 
surveillance system relying on passive reporting of events suspected by reporters to be 
vaccine related. THL keeps all the before-mentioned registers. The Vaccine Adverse Effects 
Register is going to be transferred to the care of the Finnish Medicines Agency when the new 
Communicable Diseases Act enters into force in March 2017. The epidemiological 
surveillance of adverse effects will remain at THL.  
This thesis describes the disease burden and cost-effectiveness studies related to three 
vaccines, the introduction of which was considered in Finland during the period 2001–2011. 
These studies were carried out specifically to provide data to inform decision-making 
following the process described above. The thesis also shows how the utilization of Finnish 
registers in estimating the disease burden has improved during the 10-year period in which 
this study was undertaken.  
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2 Aims of the study  
The purpose of the study was to estimate the burden and costs of three potentially vaccine-
preventable diseases and conduct an economic evaluation of two vaccination programmes in 
Finland. The detailed objectives were: 
1) to estimate the burden and costs of potentially vaccine-preventable diseases 
(pneumococcal diseases, influenza related diseases in children, human papillomavirus 
related genital diseases in women), 
2) to assess the cost-effectiveness of pneumococcal conjugate vaccination programme 
for infants,  
3) to assess the cost-effectiveness of influenza vaccination programme of healthy 
children. 
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3 Review of the literature  
3.1 Economic evaluation in health care 
Decision-makers make choices and decisions on how to allocate scarce resources in health 
care. Economic evaluations are used as a tool and aid for decision-making in allocating the 
economic resources as optimally as possible. Information is needed on efficiency, 
distributional changes, and the fairness of the potential re-allocations following the decisions 
(11). In the economic evaluation, alternative interventions are systematically compared in 
regard to both their costs and consequences. 
In economic evaluations, both the inputs (costs) and outputs (consequences) of the relevant 
alternative interventions are evaluated. Different types of economic evaluation measure costs 
in a monetary value but vary in how the consequences (health effects) of an intervention are 
evaluated (11). In the cost-benefit analysis (CBA), the health effects are translated into 
monetary units. In the cost-effectiveness analysis (CEA), the health effects are measured in 
terms of natural units related to the intervention (e. g. deaths averted, life-years gained). In 
the cost-utility analysis (CUA) the health effects are measured in terms of combined changes 
in the quality and quantity of life (mortality), typically expressed in Quality-Adjusted Life-
Years (QALYs) gained. 
The number of QALYs gained is a widely used effectiveness measure in evaluating health 
care interventions (11). It is a composite measure that combines both the impact of an 
intervention on life expectancy (mortality) and health-related quality of life (morbidity). In 
the QALY framework each period of time in a given state may be assigned a utility value. A 
scale from zero (representing death) to one (representing full health) has become the 
conventional scale for QALY weights. The utility value corresponds to health-related quality 
of life during that period. 
In the context of welfare economics, individuals are assumed to be the best experts in judging 
their own welfare, which is expressed in terms of individual utility (12). Social welfare is the 
sum of these individual utilities. According to the Pareto principle an improvement in social 
welfare occurs if an intervention increases the utility of at least one individual without 
making anyone else worse off. Pareto-efficiency is an allocation of resources to which no 
reallocation can be made without reducing at least one individual’s utility. 
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In reality there are few situations where an intervention could be judged by the Pareto 
principle. The acknowledged problem of the Pareto principle is that usually public 
programmes favour some individuals (gainers) and disfavours others (losers) (12, 13). A less 
restrictive Kaldor-Hicks criterion has been developed to solve the problem of losers. If after 
an intervention those who benefit could hypothetically compensate those who lose and still 
be left better off, the situation would constitute a Kaldor–Hicks improvement or potential 
Pareto improvement. The compensation does not actually have to take place and the fairness 
or distribution of utility in society is not taken into account. This constitutes the welfare 
economic foundation of CBA. 
In the welfarist approach, the aim is to maximise overall welfare. Welfarism has been argued 
as being too narrow an approach, since it is judging social welfare simply in terms of 
individual preferences (11). Furthermore, there are other things that cannot be ignored in 
making social choices. There are goods and services that have been considered as so 
important, even meritorious, to society that it is reasonable to argue that they should be 
provided or subsidised in a society and special attention should be paid to the equity and 
equality in their distribution. In practice, concerns about the use of CBA in decision-making 
regarding publicly funded health care interventions have related to the unwillingness to value 
the length and quality of life in terms of money and the distributional inequity following from 
the admitted fact that the willingness-to-pay of welfare is also affected by ability to pay (13, 
14).  
In the extra-welfarist approach, the aim is usually to maximise just health itself. The extra-
welfarist approach also uses other outcomes than utility and other sources of valuation than 
the affected individuals (15). Furthermore, it weights the outcomes with other than 
preference-based principles and makes interpersonal comparisons of well-being in a variety 
of dimensions. In the extra-welfarist approach, the health effects are usually measured as 
QALYs gained. In a CEA carried out with QALYs from an extra-welfarist perspective, the 
assessment of social welfare is based on an external evaluation of individuals targeted in the 
intervention (13).  
There are also concerns in the use of CEA with QALYs in evaluating publicly funded health 
care interventions. The approach has been criticised for ignoring or at least underestimating 
the non-health benefits of the intervention and for setting maximization of health as the only 
goal of societal decision-making (13). In addition, CEAs cannot be directly used in decision-
making since judging the intervention using the CEA requires a given threshold for the cost 
per QALY gained when the alternative is more expensive and more effective. Thus, a 
decision-maker has to specify a threshold value for the incremental cost-effectiveness ratio 
(ICER) below which the intervention becomes acceptable. 
A comparison of interventions has to be made at a single point in time. The future costs and 
benefits are adjusted for differential timing by discounting, in which case costs and benefits 
are reduced to the same point of time. Curative and preventive interventions differ in timing. 
When the costs and benefits of curative interventions occur usually at the same time in 
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preventive interventions, such as in vaccination programmes, there are usually different time 
profiles for costs that occur now and benefits that occur in the future (11). Thus, the longer 
the delay in benefits obtained from the vaccination, the greater is the influence of 
discounting. In evaluating health interventions, the used discount rate usually rests on the 
social rate of time preference, which is the rate that reveals society’s preferences for 
consumption in one time period compared with another (16). In addition, there has been 
much debate on whether both costs and health effects should be discounted at an equal or 
differential rate. In most countries, the national guidelines recommend equal discounting. 
However, equal discounting has been criticised as favouring curative interventions over 
preventive ones. Differential discounting is used at least in Belgium, the Netherlands and 
Poland (17). Jit and Mibei (18) conclude that compared to equal discounting, differential 
discounting appears to be fairer from an inter-generational perspective, since discounting will 
reduce the value of future health and the consumption gains of the current and future 
generation.   
3.2 Direct and indirect effects of vaccination  
Prophylactic vaccines are given to non-infected individuals in order to prevent infections. 
The direct effects of vaccination reduce the susceptibility of a vaccinated individual to 
contract the infection or disease, or reduce the infectiousness of a vaccinated individual (3, 
4). The indirect effects in an individual result from changes in exposure to infection due to 
the direct effects on the other, vaccinated individuals in the population. The indirect effects 
affect both vaccinated and unvaccinated individuals. 
The direct effect of vaccination is defined as the reduction in the risk of infection in a single 
vaccinated individual when everyone else remains unvaccinated. The direct effect of 
vaccination (vaccine efficacy) is typically studied in an individually randomised controlled 
trial under ideal conditions, where an equality of exposure to infection and a baseline equality 
between the vaccinated and unvaccinated groups with respect to relevant risk factors can be 
assumed through randomisation (3).  
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In practice, many of the effects of vaccination are effects of the vaccination programme. 
Effects can also be classified according to whether they affect vaccinated or unvaccinated 
individuals. Figure 2 presents how these effects in vaccinated, unvaccinated, or the whole 
population are defined, and they can be estimated, at least ideally, by comparing appropriate 
subgroups (3, 4, 9). The indirect effect on a vaccinated individual is the reduction in the risk 
of his or her infection due to other individuals being vaccinated in the population. 
Theoretically it could be estimated by comparing a vaccinated individual in a partially (or 
even wholly) vaccinated population A with a vaccinated individual in population C, in which 
everyone else is unvaccinated. In practice, it may be impossible to distinguish the direct and 
indirect effects on the vaccinated individual. The total effect of the vaccination on a 
vaccinated individual is the reduction in the risk of infection due to the direct and indirect 
effects of the vaccination. It can be estimated by comparing vaccinated individuals in a 
partially vaccinated population A with unvaccinated individuals in an unvaccinated 
population B.   
The indirect effect on an unvaccinated individual is the reduction in his or her risk of 
infection due to vaccinating other individuals in the population. It can be estimated by 
comparing unvaccinated individuals in a partially vaccinated population A with unvaccinated 
individuals in an unvaccinated population B. The total and indirect effects of vaccination on 
an unvaccinated individual are the same, since an unvaccinated individual does not gain 
direct protection by the vaccination. Finally, the overall public health effect of the 
vaccination (effectiveness of vaccination programme) is defined as the weighted average of 
the corresponding risk reductions due to indirect effects on the unvaccinated individuals and 
the total effects on the vaccinated individuals.  
The protective effect of a vaccination can be measured by the reduction in either acquiring 
the infection or contracting the symptomatic disease. As an example, the pneumococcal 
conjugate vaccine (PCV) has been shown to reduce both the nasopharyngeal carriage (19) 
and invasive disease (20) due to vaccine-type pneumococci. When the indirect effect of 
vaccination reduces the risk of infection or disease it is called the herd effect. For example, it 
depends on the direct efficacy, the vaccination coverage, and on how the unvaccinated and 
vaccinated groups mix in the community. Indirect effects are not always favourable. For 
example, a shift in the age distribution of the first infection toward older ages is an indirect 
effect that may be unfavourable if the infection later in life causes more serious disease (4). 
This is a particular problem with rubella, which has its most severe consequences in the first 
trimester of pregnancy (5). Another example is a vaccine-induced pneumococcal serotype 
replacement in which the vaccine-serotypes may be replaced with more invasive non-vaccine 
serotypes as causes of nasopharyngeal carriage and disease (6-8).  
Transmission models have been used to investigate the underlying dynamics of infectious 
diseases and to predict the overall effectiveness of vaccination programmes (8, 21). These 
models have been utilised increasingly in cost-effectiveness evaluations of vaccination 
programmes (22, 23). 




Figure 2. Conceptualisation of different vaccination effects in vaccinated individuals, 
unvaccinated individuals, or in the whole population.  
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3.3 Economic evaluation of the pneumococcal conjugate 
vaccination programme  
3.3.1 Streptococcus pneumoniae and pneumococcal diseases  
Streptococcus pneumoniae, or pneumococcus, is a bacterial species that consists of more than 
90 immunologically distinct serotypes. These serotypes are further grouped into 46 
serogroups, based on immunological similarities (24). Pneumococcus enters humans through 
the respiratory tract and can remain on the nasopharyngeal surfaces without causing 
symptoms (25). Pneumococci residing in the nasopharynx of children are the reservoir for the 
spread of species between people. Occasionally the pneumococcus proceeds from the 
nasopharynx and invades normally sterile sites or body fluids, causing disease.  
The spectrum of pneumococcal diseases is wide. The invasive pneumococcal diseases (IPD), 
such as meningitis, bacteraemia and bacteraemic pneumonia, occur most commonly in 
children <2 years of age and in older people. The pre-vaccination IPD incidence per 100 000 
person-years in children <2 years of age has been close to 200 in the USA (26), and 50–60 in 
the UK (27) and Finland (28). In older people (≥65y), the corresponding rates have been 
around 60 in the USA, 35 in the UK, and 30 in Finland. The variation in the reported IPD 
incidence in young children between Western Europe and North America has been well-
known and is usually explained by more frequent blood-culture practices in the USA, notably 
in less severe bacteraemia cases (29). Thus, less severe IPD cases may be under-detected in 
Europe.  
Increasing age, race, chronic medical conditions, conditions causing immunodeficiency as 
well as socioeconomic environmental and behavioural factors are known risk factors for 
pneumococcal diseases. Different proportions of these populations at risk affect national 
differences in the incidence of pneumococcal diseases. The non-invasive infections 
(pneumonia, sinusitis, mastoiditis, acute otitis media) are typically less severe but more 
common manifestations of pneumococcal infection (30-32). The national differences in the 
incidence of the non-invasive diseases may be due to differences in case definition, study 
designs, diagnostic procedures, and management of the disease, for example, in antibiotic 
prescribing practices. The clinical diagnosis has varied between countries and studies. In 
addition, because the causative pathogen of non-invasive infections is rarely identified, the 
etiological diagnosis often remains unclear.  
Community-acquired pneumonia (CAP) causes a significant burden of disease. As in IPD, the 
incidence of CAP is highest among young children and older people and varies greatly by 
study and country (30, 33). A Finnish study (34) has reported the highest annual age-specific 
pre-vaccination incidence rate (per 1000 person-years) of CAP in children aged <5 years 
(36.0) and in older people aged ≥75 years (34.2). As expected, the lowest incidence was 
reported in the population aged 15–74 years (8.8). In two population-based Finnish studies, 
the annual pre-vaccination incidence rate per 1000 person-years of hospital-diagnosed 
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pneumonia was 13.3 for children aged <5 years (35) and of CAP 15.8 for older people aged 
≥65 years (36). In Finland, 37% of bacterial CAP was potentially due to pneumococcus in 
hospitalised children in 1993–1995 (37) and 17% in radiologically confirmed CAP in older 
people in 2005–2007 (36).  
Elsewhere in Europe, CAP incidence has varied from around 3 (38) to 14 (39) per 1000 
person-years among older people. In the UK (40) and Norway (41), CAP incidence was 
around 3 per 1000 person-years in children aged <5 years.  
Acute otitis media (AOM) is one of the most common infections affecting infants and young 
children, and one of the main reasons for antibiotic treatment (42, 43). The incidence of 
AOM has varied greatly between studies. The pre-vaccination incidence of acute otitis media 
among children aged <2 years was reported to be 1.24 episodes per person-year in a 
prospective, randomised, double-blind cohort study from Finland (44) and 0.282 episodes per 
person-year in a retrospective cohort study from the Netherlands (45). In a prospective birth 
cohort study from Germany, during the first 2 years of life, a child had on average 2.2 
episodes of AOM and during the first 12 months of life on average 50.6% of children with 
AOM were treated with antibiotics (46).  
3.3.2 Pneumococcal conjugate vaccines and the effectiveness of the 
vaccination programme 
Vaccines 
The first pneumococcal vaccine, the polysaccharide vaccine (PPV), was licensed in the late 
1970s. In adults PPV has shown to effectively prevent IPD and has been associated with 
some reductions in non-bacteraemic pneumonia but not in upper respiratory tract infections 
(47, 48). PPV has not been shown to be effective in children aged <2 years.  
To improve the immune response to the capsular polysaccharide in young children, novel 
vaccines in which capsular polysaccharides are conjugated to one of several different proteins 
were developed and tested (49). The first pneumococcal conjugate vaccine (PCV), containing 
7 serotypes of Streptococcus pneumoniae (Prevenar®) was licensed in the USA in 2000. A 
year later (2001) it was granted a central marketing authorisation by the European 
Commission in 2001. PCV7 contains capsular polysaccharide antigens of seven serotypes (4, 
6B, 9V, 14, 18C, 19F, and 23F).  
PCV7 was first introduced in the US NVP in 2000 (50). Afterwards, it has been widely 
introduced in vaccination programmes, for example, in Australia (2005), Canada (2005), the 
UK, the Netherlands, and Norway (2006), Belgium (2007), and Sweden (2009) (51). PCVs 
containing 10 (Synflorix®) and 13 (Prevenar 13®) serotypes of Streptococcus pneumoniae 
were granted a central marketing authorisation in 2009 (52, 53). Since that time, PCV7 has 
been replaced by PCV10 or PCV13. In Finland PCV was included in the NVP in 2010 in the 
form of PCV10.  
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PCV efficacy and effectiveness trials 
The efficacy of PCV7 against IPD was first shown in the Northern California Kaiser 
Permanente (NCKP) efficacy trial. The vaccine efficacy of PCV7 against vaccine-serotype 
(VT) IPD was reported to be 97.4% in the per-protocol analysis and 93.9% in the intention-
to-treat analysis (54). In the intention-to-treat analysis the vaccine efficacy of PCV7 against 
any IPD was reported to be 89.1% (54), against all clinically diagnosed pneumonia 4.3% 
(55), and against episodes with a positive radiograph 17.7% (55).  
PCV7 has also been shown to reduce otitis media in young children. In the per-protocol 
analysis, the efficacy of PCV7 against all otitis media episodes was 7.0% in the NCKP trial 
(54) and 6.0% in the Finnish Otitis Media Vaccine Trial (44).  
In a Finnish nationwide cluster-randomised double-blind trial (FinIP), PCV10 total (direct + 
indirect) effectiveness against culture-confirmed IPD (irrespective of serotype) was reported 
to be 93% (20) and against suspected IPD (non-laboratory-confirmed) 62% (56). There are no 
published randomised controlled trial data assessing the clinical efficacy of PCV13 against 
IPD. However, the vaccine efficacy has been shown in non-inferiority trials by comparing the 
PCV13 immunogenicity (antibody concentrations) to that of PCV7, which has demonstrated 
efficacy against pneumococcal diseases (57-59). In addition, PCV13 has been shown to 
reduce nasopharyngeal colonization of the additional PCV13 serotypes (59).   
There are several PCV vaccine efficacy studies, where the gain in reduced risk of VT 
nasopharyngeal carriage is partly offset by the serotype replacement of NVTs among the 
vaccinated (60-63). The impact of this replacement in carriage on the incidence of IPD 
depends on the difference in the invasiveness of the replacing serotypes and replaced 
serotypes (7, 8).  
Impact of PCV in national vaccination programmes 
At the population level the indirect effects of the vaccine programme are due to changes in 
the pneumococcal serotype circulation in the vaccinated population. The risk of VT carriage 
is further reduced among the vaccinated and unvaccinated. The NVT replacement offsets the 
gain in reduced risk of VT carriage and disease both in the vaccinated and unvaccinated. 
Replacement in carriage has been reported in several observational post-licensure PCV7 
studies (64-67). Weinberger and colleagues (7) have suggested that since the replacement in 
disease has not been as complete as in carriage, the invasiveness of the replacing serotypes 
may be lower. In addition, potential biases in the pre-vaccination carriage data and the 
disease surveillance systems could underestimate the replacement in disease. 
The first post-vaccination year estimates of the effects of the PCV7 programme on IPD 
incidence rates among the vaccinated and unvaccinated come from the USA. Among the 
unvaccinated the rate of IPD incidence was reported to decrease by 32% in those aged 20–39 
years, 8% in those aged 40–64 years, and 18% in those aged ≥65 years (68). Later post-
vaccination surveillance in the USA and Europe has showed that the PCV7 programme has 
decreased VT IPD in all age groups (6, 27, 69, 70). However, many studies have reported that 
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the PCV7 programme was associated with increased NVT IPD incidence in all age groups. 
Among children, the reported overall IPD incidence has still been lower than in the pre-
vaccination era (6, 27, 70). In the USA, the overall IPD incidence across all age groups has 
declined by 45% after the introduction of PCV7 (6). In England the overall reduction in IPD 
has been 56% among children aged <2 years and 19% in those aged ≥65 years and 34% 
across all age groups (27).  
An observational study comparing the hospitalisation rate for pneumonia in the USA before 
and after the PCV7 vaccination program was introduced have reported that after a decade the 
rate of pneumonia hospitalisations declined particularly in children aged <2 years (43.2%) 
and those aged 85 years and older (22.8%) (71). In the age groups between, the reduction in 
hospitalisations was reported to range from 4.5% to 13%, except in the 40–64 year olds, 
whose rate has increased modestly. It is noteworthy that the observational study design 
ignores other factors that have also been changed over time besides vaccinations and 
therefore have an additional impact on the results.  
In Finland, a population-based observational follow-up study has reported a 48% reduction in 
IPD incidence among unvaccinated children aged 2–5 years during the first three years after 
the introduction of PCV10 in the NVP (72). In the UK, PCV7 was introduced into the NVP 
in 2006 and PCV13 replaced PCV7 in April 2010. The incremental effect of PCV13 versus 
PCV7 was investigated in a national surveillance study, where the incidence of IPD in the 
epidemiological year 2013–2014 was compared to the pre-PCV13 baseline (years 2008–
2010) in England (73). The reported decline in the IPD incidence was nearly 50% among 
those aged ≤44 years, 25% among those aged 45–64 years and 25% among those aged 65 and 
older.  
3.3.3 Economic evaluations  
When PCV7 was licensed in the USA (2000) and in Europe (2001), it was the most 
expensive vaccine in the market at the time. In the first European economic evaluations, the 
assumed price per dose ranged from EUR 40 to EUR 65 (74). Decision-makers considering 
PCV7 in the public funded NVPs required evidence on the cost-effectiveness of the 
vaccination programme. Economic evaluations estimating the cost-effectiveness of PCV7 
were funded either at least partly by the manufacturer (75-92) or by government, university 
or foundation (93-102).  
In the economic evaluations, the efficacy of the PCV7 vaccination programme among the 
vaccinated was estimated from the Kaiser Permanente Pneumococcal Conjugate Efficacy 
Trial (54, 55) and the Finnish Otitis Media Vaccine Trial (44). Yet the effectiveness of the 
vaccination programmes against IPD has varied between the studies, since in most of the 
studies the vaccine efficacy has been adjusted to correspond to the country-specific serotype 
distribution (77-79, 81-84, 86-89, 91, 94-96, 100, 102). In addition, different assumptions for 
the waning immunity have caused variation.  
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Only a few economic evaluations of the PCV7 programme have reported an acceptable level 
of cost-effectiveness either from the societal (79, 80, 82) or health care provider perspective 
(78, 93), when only direct effects of the programme were taken into account.  
The assumptions on herd protection and serotype replacement have been found to be major 
factors influencing the cost-effectiveness of the PCV7 programmes (74, 103). After the first 
post-vaccination year, estimates of the effect of the PCV7 vaccination programme on IPD in 
the USA (68) had demonstrated a considerable reduction in the IPD incidence among both 
the vaccinated and unvaccinated; hence, vaccine-induced herd protection was included in 
most economic evaluations of PCV7 (83-92, 96, 100, 101). European studies have used the 
US post-vaccination estimates of decline in the IPD rate after adjusting it to correspond the 
country-specific serotype distributions. The US estimates have also been used to evaluate the 
post-vaccination cost-effectiveness of the PCV7 programme in the USA (85, 90). In addition, 
observational post-vaccination data of their own have been used in economic evaluations of 
the PCV7 programme in Quebec, Canada (92) and Australia (104, 105).  
The inclusion of herd protection using the US post-vaccination estimates in the economic 
evaluations has led to a 30–90% reduction in the cost per QALY estimate (83, 84, 86, 88, 96, 
100). In fact, these studies have concluded that the PCV7 programme is unlikely to be 
acceptably cost-effective without the inclusion of herd effect in the analysis. The assumptions 
on indirect effects are also highly influential regarding the cost-effectiveness of PCV10 and 
PCV13 programmes (106). The cost of the vaccination programme that have also been found 
to be highly influential in determining the cost-effectiveness of the PCV7 programme include 
the price per vaccination schedule (4 or 3 doses) and the administration costs.  
Economic evaluations using observational post-vaccination data were reported to be 
acceptably cost-effective (92) or even cost saving (90) from the health care perspective in 
Canada and the USA. Newall and colleagues (104) have reported that the PCV7 programme 
is unlikely to have a cost-effectiveness ratio below a conventional acceptability threshold in 
Australia at the initial vaccine price. However, if the observed reduction in CAP deaths in 
Australia was assigned to the PCV7 programme the programme was reported to be cost-
effective.  
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3.4 Economic evaluation of influenza vaccination programme for 
healthy children  
3.4.1 Influenza and influenza-related diseases in children 
Influenza virus types A and B cause an extensive burden of illness in children (107-109). 
Annually recurring epidemics vary in timing and circulating subtypes (110). The severity of 
disease varies from mild to severe infections requiring health care services. Assessment of the 
burden of influenza is not straightforward as the symptoms are non-specific and patients with 
symptoms are not routinely tested for the causing pathogen. The clinical diagnosis of 
influenza has shown to be inaccurate, especially in small children (111, 112).  
In a Finnish cohort study, the attack rates of influenza illness among children with any sign of 
respiratory infection were reported to be 17.9 for children aged <3 years old, 17.5 for children 
aged 3–6 years old, and 14.2 for children aged 7–13 years old (108). In a meta-analysis and 
economic evaluation that used the attack rates derived from placebo arms of vaccine efficacy 
trials, the attack rate of influenza was reported to be 15.20% for children aged <18 years 
(113) and 19.21 for children aged <12 years (114). The Houston Family Study has reported a 
high attack rate (33.0%) for infants aged <1 years (115).  
In a study that estimated the influenza-related proportion of health care outcomes of acute 
respiratory illness episodes in England, the influenza-related hospital admission rate was 
reported to be highest (1.9 per 1000) in children aged <5 years (109). In a prospective cohort 
study, the annual rate of hospitalisations due to influenza was reported to be 2.3 per 1000 
children aged <5 years (107).  
According to a Finnish cohort study, AOM was diagnosed in 39.7% of the children aged 
<3 years old and was reported to be the most frequent complication of influenza in all age 
groups. In a retrospective study of children treated at Turku University Hospital (Finland) 
among children with influenza A (median age 2.0 years), otitis media was developed in 26% 
and pneumonia in 9% of the children and among those with influenza B (median age 4.2) 
otitis media was developed in 19% and pneumonia in 8% of the children (116).   
3.4.2 Influenza vaccines and effectiveness of the vaccination programme in 
children 
The influenza vaccine protects against highly contagious influenza virus and is given 
annually. Inactivated influenza vaccine has been accessible since the 1940s and is authorised 
for anyone six months of age and older (110). Live attenuated influenza vaccines (LAIV) 
were licensed in the United States in 2003 (110) and in Europe 2011 (117) where it is 
authorised for persons aged 2–17 years. Inactivated vaccine is administered via intramuscular 
injection and LAIV is administered via nasal spray (110).  
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Trivalent inactivated influenza vaccine (TIV) contains three different influenza subtypes: two 
influenza A subtypes and one influenza B subtype. Quadrivalent inactivated influenza 
vaccine contains an additional influenza B subtype and is gradually becoming available in 
Europe (117). Also quadrivalent LAIV4 has been available from season 2014–2015.  
Predicting the effectiveness of an influenza vaccination programme is complicated and using 
the vaccine efficacy estimates directly from clinical trials is problematic (118). In clinical 
trials, the efficacy of TIV in children has been reported as varying from no efficacy (119) to 
over 80% (120, 121). The wide variation is largely explained by seasonal variations in the 
influenza incidence and the match between the vaccine and circulating subtypes of the virus 
(118, 122). In the clinical trials performed during seasons with a good vaccine match, the 
effectiveness of TIV has been 50 to 80%, whereas studies with a poor or suboptimal match 
have reported lower estimates of vaccine effectiveness (122). According to clinical trials the 
effectiveness of LAIV is better than the effectiveness of TIV. In a meta-analysis of nine 
randomised clinical trials the efficacy of LAIV when compared to placebo was reported to be 
72% against any subtype of influenza virus (123). A large trial comparing LAIV and TIV in 
children aged 6–59 months has reported 55% higher relative efficacy of LAIV compared with 
TIV (124).  
There are also other factors that make predicting the impact of vaccination programme 
difficult. Accuracy in case ascertainment varies between clinical trials due to differences in 
endpoints, clinical diagnosis and virological testing (118). In addition, the indirect (herd) 
effect of the vaccination programme may substantially increase the overall effectiveness of 
the vaccination programme (125). The importance of children as transmitters of the influenza 
infection has been shown in clinical trials (126-128). The potential in preventing influenza in 
the entire population by vaccinating children has received increased attention. Several 
dynamic models constructed to investigate the transmission of influenza infection in the 
population and the effect of vaccinations has shown that targeting vaccinations in children 
effectively prevents influenza in the entire population (129-131).  
3.4.3 Economic evaluations  
Economic evaluations of influenza vaccinations in healthy children have been performed for 
TIV (114, 130, 132-142), for LAIV (143-145), and for both vaccines (146-148). Only a few 
studies have estimated the incremental cost-effectiveness of LAIV compared to TIV (149, 
150). The cost-effectiveness was assessed in different age groups. In some studies, the cost 
effectiveness was investigated only in small children. In these studies the cost-effectiveness 
was investigated in children whose ages ranged from 6 months to 2–5 years (136, 137, 144, 
146) or in children whose ages ranged from 15–24 months to 5–6 years (134, 143, 149). In 
other studies, school children and teenager were also included in the analyses. In these studies 
the cost-effectiveness was investigated in children whose ages ranged from 6 months to 13–
18 years (130, 133, 135, 147) or from 2–5 years to 14–18 years (138-140, 145, 148, 150).    
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Some of the studies reported TIV vaccinations to be cost-saving from a societal perspective 
but acceptably cost-effective from a health care provider perspective (132, 137-140). For 
example, in economic evaluations of TIV in children aged 6–60 months (137), in children 
aged 3–14 years (138), and in children aged 5–17 years (140), the ICER of the programme 
was reported to be under EUR 15 000 per QALY gained from the health care provider 
perspective. Prosser and colleagues (147) have reported that the cost-effectiveness of TIV 
decreases with age. The ICER was reported to be ≤USD 28 000 in children younger than 5 
years old and USD 79 000 in children aged 5–11 years. The ICER of the LAIV vaccination 
programme in children aged 12–18 years was reported to be under EUR 1000 per QALY 
gained from the health care provider perspective. From the health care provider perspective, 
TIV vaccinations were reported to be cost-saving in children aged 6–59 months (146) and in 
children aged 6 months to 13 years (135).  
The economic evaluations vary substantially due to many choices concerning methodological 
and modelling issues that apparently affect the cost-effectiveness estimates of the 
vaccinations. The inclusion of a societal perspective (e.g. productivity costs due to parental 
work absenteeism because of taking care of the sick child) has improved the cost-
effectiveness ratio of the vaccinations in the studies. Some studies counterbalanced the 
productivity costs by costs of taking the child to the vaccination visit (132, 134-137, 143, 
145-147, 150). Likewise, including the indirect protection of non-vaccinated age groups were 
found to improve the cost-effectiveness ratio. Only a few economic evaluations have been 
based on a dynamic transmission model (130, 140, 148) and some have included an indirect 
herd effect in their static model by reducing the secondary attack rate of influenza among 
household members of vaccinated children (132, 134, 136, 137, 139, 144-146, 149, 150). A 
static model, even if taking into account the secondary cases in the families of the vaccinated 
children, is likely to underestimate the benefits of the vaccination programme.  
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3.5 Economic evaluation of HPV vaccination programme  
3.5.1 HPV infection and HPV related diseases 
Cervical human papillomavirus (HPV) infection is a common sexually transmitted infection. 
A recent meta-analysis of 1 million women with normal cytological findings has estimated 
the global HPV prevalence to be approximately 12% (151, 152). HPV prevalence is known to 
vary by age and geographical region. The prevalence has been reported to be highest in Sub-
Saharan Africa (24.0%), Eastern Europe (21.4%) and Latin America (16.1%) and lowest in 
Western Asia (1.7%). In Northern Europe, the prevalence has been reported to be 10%. In all 
regions, the first HPV peak prevalence has been reported to occur in women under the age of 
25 years (152). In Finland, the HPV prevalence rate was reported to be 7.5% among women 
aged 25–65 years attending the organised cervical screening and 24.1% among women aged 
25–29 years (153). In young women, when the infection is most prevalent, about 90% of the 
HPV infections clear within two years (154).  
The link between HPV and cervical cancer was shown in the 1980s (155). HPV is considered 
a necessary but not sufficient factor for the development of cervical cancer (156, 157). In 
addition, HPV is also known to cause a substantial proportion of anus, penis, vagina, vulva 
and head and neck cancers (158, 159).  
More than 100 HPV types have been identified, 40 of them cause infections in the genital 
tract (160). High-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 
82) are associated with invasive cervical cancer. Persistent high-risk HPV infection may lead 
to cervical intraepithelial neoplasia (CIN1–3) and progress further to invasive cancer (161). 
HPV types 16 and 18 are responsible for about 70% of all cervical cancer cases (156, 162) 
and about 50% of CIN 2/3 (163).   
The incidence of cervical cancer is known to vary widely by region. Arbyn and colleagues 
(164) have reported the rates estimated from the GLOBOCAN 2008 database that provides 
estimates of the incidence from common cancer types for 184 countries of the world. The 
highest age-standardised cervical cancer incidence rates are in Eastern, Southern and Western 
Africa (>50/100 000) and the lowest in Western or South-Central Asia e. g. Gaza and West 
bank (<1/100000). In Europe, the lowest age-standardised incidence rates are in Malta, 
Finland, Greece, and Switzerland (≤4.0/100 000).  
Screening has had a considerable impact on the incidence of cervical cancer (165, 166). The 
CIN cases are effectively found by the screening system. Therefore, the detected number of 
CIN cases reflects the screening practice of the country in addition to the disease burden.  
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3.5.2 Primary and secondary prevention of cervical cancer  
Secondary prevention of cervical cancer was introduced in the 1960s in Finland (167). 
Cervical cancer screening has been based on the cytological Pap (Papanicolaou) test. 
Organised, population-level cytological screening can reduce the incidence of cervical cancer 
by up to 80% (165). According to the European Union recommendation, cancer screening 
should only be performed in population-based, organised screening programmes.  
Primary prevention against cervical cancer has been available since 2006. Bivalent (types 16 
and 18) and quadrivalent (types 6, 11, 16, and 18) HPV vaccines prevent HPV types that 
cause the most cervical cancers and a portion of the cancers of the anus, vulva, vagina, penis 
and oropharynx (168-170). The quadrivalent vaccine prevents, in addition, HPV types that 
cause most genital warts. The 9-valent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, and 
58) was granted marketing authorisation in Europe in June 2015 (171).  
The first group of countries to introduce the HPV vaccination into national immunization 
programmes in 2006–2007 were e. g. USA, Belgium, UK, Australia, and Canada. By the end 
of 2012, the HPV vaccination had been introduced into the NVP already in more than 40 
countries (172, 173). All Nordic countries have included HPV vaccination in the NVP: 
Norway and Denmark in 2009, Iceland in 2011, Sweden in 2012, and Finland in 2013. 
Both bivalent and quadrivalent vaccines have demonstrated high efficacy against vaccine 
type HPV infection (169, 174, 175). In addition, both vaccines have shown cross-protection 
against non-vaccine HPV types (176, 177). In a meta-analysis, the bivalent vaccine was 
reported to have better cross-protection against non-vaccine HPV types 31, 33, and 45 than 
the quadrivalent vaccine (178). However, the differences were not all significant and the 
results might suggest waning cross-protection. An indirect herd effect has been shown in 
Australia, where the HPV vaccination programme for all women aged 12–26 years have 
decreased the genital warts incidence both in vaccinated women and non-vaccinated 
heterosexual men (179).  
3.5.3 Economic evaluations  
The early economic evaluations of HPV vaccination programmes targeting adolescence girls 
were based on static cohort models and therefore were unable to explore the indirect herd 
effect of the vaccination programme (180-182). Recent economic evaluations are based on 
both static models and dynamic transmission models.  
In the Netherlands the HPV vaccination programme was assessed to be acceptably cost-
effective (EUR 19 430 per QALY gained) by Coupé and colleagues (183) but not cost-
effective (EUR 53 500 per QALY gained) by de Kok and colleagues (184), with a Dutch 
willingness to pay threshold of EUR 20 000 per QALY. The main reason for the difference in 
results in these two studies was in the used discount rates. Coupé and colleagues used a 4% 
discount rate for costs and 1.5% for effects according to the national guidelines, while de Kok 
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and colleagues used a 3% discount rate for both costs and effects. Both analyses were based 
on a static cohort model. In an analysis that was based on a transmission dynamic model, the 
HPV vaccination programme was reported to be cost effective (GBP 22 500 per QALY 
gained) at a willingness to pay threshold of GBP 30 000 per QALY gained in the UK (185). 
In a static model, the cost-effectiveness ratio was estimated to be CAD 31 000 for bivalent 
vaccine and CAD 21 000 quadrivalent vaccine per QALY-gained in Canada (186).  
According to several reviews, vaccinating girls against HPV before their sexual debut is 
likely to be cost-effective (187-189). The duration of vaccine-induced protection, vaccination 
costs, and discount rate were among the parameters that were most influential on the results 
of the economic evaluations.  
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4 Materials and methods  
In this study, we conducted economic evaluations of the infant 7-valent pneumococcal 
conjugate vaccination programme (I) and childhood influenza vaccination programme (II), 
and also a burden of disease analysis of HPV-related genital diseases in women (III, IV).  
The incidence of the pneumococcal, influenza and HPV-related disease outcomes and the 
disease-related health care resource use were estimated from register data and 
epidemiological studies.  
The economic evaluations in articles I and II were based on a static cohort model where only 
the effect of the vaccination programme on the vaccinated was included in the analyses. In 
order to investigate the impact of indirect effects on the cost-effectiveness of the infant PCV7 
vaccination programme among the unvaccinated, an economic re-evaluation by means of a 
static model was conducted in 2008 (PCV7-II) when PCV7 was reconsidered to be included 
into the NVP. The methods and results of the unpublished economic re-evaluation of the 
PCV7 vaccination programme (PCV7-II) are also presented here. In this thesis, the first 
evaluation is referred to as PCV7-I (published in article I) and the second as PCV7-II 
(previously unpublished).  
4.1 Models  
The models used in the economic evaluations and the overview of the studies are shown in 
Table 1. In the economic evaluations of the PCV7 vaccination programme, unvaccinated and 
vaccinated hypothetical birth cohorts were followed from birth until 5 years (PCV7-I) or 100 
years (PCV7-II) of age in a Markov cohort model. The transition probabilities between 
Markov states were estimated from annual, age-specific incidence rates for pneumococcal 
disease outcomes in Finland. In the first study (PCV7-I) the health states of the Markov 
model were pneumococcal meningitis, pneumococcal bacteraemia, community-acquired 
pneumonia (CAP), acute otitis media (AOM), death, and no pneumococcal disease. In the 
second study (PCV7-II) the health states were pneumococcal meningitis, pneumococcal 
bacteraemia, pneumonia treated in secondary health care, pneumonia treated in primary 
health care, AOM, pneumococcal death, death from other causes, no pneumococcal disease.  
  
   
36 
 
Table 1. Model and study design 
 PCV7-I PCV7-II Influenza HPV 
Publication year 2005 (I) Previously unpublished 2006 (II) 
2013 (III), 2014 
(IV) 
Study type  CEA, CUA, CBA CUA, CEA CEA Cost of illness, retrospective 
Perspective Health care, societal Health care 
Health care, 
societal Health care 
Discount rate1  3 % 5 % N/A N/A 
Price level1  2004 2007 2004 2010 






Effect on the vaccinated  Yes Yes Yes N/A 
Effect on the unvaccinated  No Yes No N/A 
Time horizon, years 5 100 1 (one season) 1 
Duration of direct 
protection, years 5 5 1 N/A 
Vaccine coverage (%) 100 % 97 % 100 % N/A 
Vaccine schedule  4 doses 3 doses 




Vaccine price (EUR) per 
dose1  50.5 48 2.3 N/A 
     





Number of cases, 
health care costs 
Size of population followed 57 574 58 000 56 000 N/A 
 
N/A, not applicable 
 1in the original publication (I, II, III, IV) or original study (PCV7-II) 
 
  
   
37 
 
In both cost-effectiveness analyses of the PCV7 programme, (PCV7-I, PCV7-II) the direct 
effect of the vaccination was assumed to last for 5 years. In the second evaluation reassessing 
the cost-effectiveness of the PCV7 programme, the indirect herd effect of the vaccination 
programme (herd effect and serotype replacement) was incorporated, assuming the reduction 
in the pneumococcal disease outcomes over the unvaccinated population (≥5 years of age) to 
occur when a steady state has been reached after the initiation of the programme. Thus, an 
external indirect herd effect factor was applied in the static cohort model. In the model, the 
indirect herd effect was assumed to occur annually for a steady-state population. The model 
was run in monthly cycles for the first 6 years and in annual cycles for the following 94 
years.  
In the economic evaluation of childhood influenza vaccination programme, unvaccinated and 
vaccinated hypothetical annual age cohorts aged from 6 months to 13 years were compared in 
a decision analysis model. The model considered the following disease outcomes: 
uncomplicated influenza, influenza with AOM, influenza with sinusitis, influenza with 
pneumonia (treated as outpatients), severe influenza (treated in secondary health care). In the 
model, all influenza- and vaccination-related costs and benefits took place during the 
concurrent influenza season. Only cases that received medical attention were included in the 
analyses.  
In order to assess the total burden and health care provider costs of prevention, management, 
and treatment of female HPV-related genital disease outcomes in Finland, we conducted a 
cost of illness study. This retrospective population-based registry study included all organised 
and opportunistic screening tests. 
4.2 Burden and costs of potentially vaccine-preventable diseases  
In order to estimate the incidence of pneumococcal-, influenza- and HPV-related disease 
outcomes as well as the health care resources used for the management and treatment of the 
disease outcomes, we established datasets as shown in Table 2. The datasets contain data 
from nationwide or regional population-based registers, epidemiological studies, and one 
vaccine efficacy trial. The population-based register data were extracted by identifying the 
individuals and the health care resource use for the disease in question.  
In Finland, individual-level administrative register data are available that are linkable using 
the unique personal identity code. The personal identity code remains unchanged throughout 
the person’s lifetime and is used for identification in practically all administrative registers in 
Finland. The individual-level register data were retrieved either with an encrypted personal 
identity code (PCV7-I, PCV7-II, II) or with the unique personal identity code (III, IV).  
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In the encrypted data, the identity code was encrypted within each register, hence, we were 
able to identify each individual’s events within each register (provider) but not between the 
registers (providers). Thus, we were not able to identify the whole treatment episode for an 
individual. For example, a patient that has first contacted primary care may be referred to 
secondary care during the illness. Double counting the individual from the unlinked registers 
was avoided by using one data source (e. g. IPD, influenza) or using an epidemiological study 
(pneumonia) when estimating the incidence of disease outcomes from register data. The 
dataset containing the unique personal identity code itself (III, IV) provided information for 
categorising the individuals according to the most severe HPV-related disease outcome by 
linking each individual’s events within and between the different registers.   
4.2.1 Epidemiological data  
From the population-based register data we identified all individuals who had at least one 
outcome related to the disease outcome in question recorded in the appropriate health 
register. The case definitions were as specific as possible from the data available. The 
incidence of disease outcomes that were estimated from the register data were assessed by 
dividing the outcome cases by age-specific population estimates for Finland (Official 
Statistics of Finland, OSF) for the corresponding time period. The age-specific background 
mortality rate was obtained from Causes of Death statistics (OSF). 
The influenza data source differed most from the others. The incidences of influenza and its 
complications (II) were obtained from an epidemiological study (108). The cases were 
laboratory confirmed but uncertainty lies in the seasonal variability of influenza epidemics. 
On the other hand, all incidences of HPV-related disease outcomes (III) were estimated from 
nationwide population-based register data. In the economic evaluations of the PCV7 
programme, the incidences of IPD and otosurgical procedures (PCV7-I, PCV7-II) and the 
incidence of pneumonia in secondary health care (PCV7-II) were estimated from nationwide 
population-based register data. The incidence of pneumonia in the first PCV7 evaluation 
(PCV7-I) were obtained from an epidemiological study and the incidence of AOM (PCV7-I, 
PCV7-II) was obtained from a vaccine efficacy trial. The incidence of pneumonia in primary 
health care (PCV7-II) was estimated using several data sources. 
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Table 2. Burden of disease datasets, epidemiological data 
PCV7-I PCV7-II Influenza HPV 
Publication year 2005 (I) Unpublished 2006 (II) 2013 (III), 2014 (IV) 
Target population, age 0–4y All ages 6m–13y Females 15+y 
Registers (individual-level data)     
Data linkable between registers No No No Yes 
Data linkable within register Yes Yes Yes Yes 
Health Care Register1, 3  1996–1999 2000–2006 N/A 1999–2008 
National Infectious Disease Register3 1995–2000 2000–2006 N/A N/A 
Finnish Cancer Registry3 N/A N/A N/A 1990–2008 
Mass Screening Registry3 N/A N/A N/A 1999–2008 
SII2 Register of Special Reimbursements for 
Medical Expenses3 1996–1999 2000–2005 N/A 1999–2008 
SII2 Register of Prescribed Medicines3 N/A N/A N/A 2004–2008 
Register of the Finnish Student Health Service3 N/A N/A N/A 1999–2008 
HUSLAB Pathology Laboratory Register4 N/A N/A N/A 2004–2008 
Primary health care data4  N/A 2001–2006 N/A N/A 
Turku University Hospital Register, hospital 
emergency department visits4 N/A N/A 1988–2004 N/A 
Registers (aggregated data)     
Cause of Death Statistics, OSF3 1997–2001 1996–2005 1997–2002 1990–2008 
Life expectancy, Population and Cause of Death 
Statistics, OSF3 Yes Yes Yes Yes 
Epidemiological studies 
FinOM vaccine trial5 (44) Yes Yes N/A N/A 
Incidence of AOM in Western Finland6 (190) Yes Yes N/A N/A 
Aetiology of paediatric CAP in Eastern Finland6 
(191) Yes Yes N/A N/A 
Incidence and outcome of IPD in Finland 1995-
20023, 7 (192, 193) Yes Yes N/A N/A 
Respiratory infections in children aged 0–13 
years6 (108) N/A N/A Yes N/A 
 
N/A, not applicable 
1 former Hospital Discharge Register  
2Social Insurance Institution  
3 Nationwide data 
4 Regional data 
5 Randomised, double-blind cohort study 
6 Cohort study 
7A population-based registry study 
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4.2.1.1 Pneumococcal disease outcomes (PCV7-I, PCV7-II)  
The incidence of invasive pneumococcal disease (IPD) was estimated from laboratory-
confirmed cases retrieved from the National Infectious Disease Register. Data from six-year 
periods 1995–2000 and 2000–2006 were used for the first (PCV7-I) and second (PCV7-II, 
Table 3) evaluations, respectively. In both evaluations, the case fatality ratio for IPD was 
obtained from a Finnish population-based registry study linking the laboratory-confirmed 
IPD cases from the National Infectious Disease Register to their vital status in the National 
Population Information System (192). The case fatality ratio was 1.2%, 9.7%, 14.5% and 
22.9% for IPD cases aged <18 years, 18–49 years, 50–74 years and aged ≥75 years, 
respectively.  
In the first economic evaluation study of the PCV7 programme in children (PCV7-I), the 
annual incidence of potentially pneumococcal pneumonia was obtained from a prospective 
epidemiological study assessing the incidence and aetiology of CAP pneumonia in Eastern 
Finland (191). According to the Jokinen study (191), the all-cause definite pneumonia 
incidence per 1000 children aged 0 to 4 years was 14.5 for inpatient treated pneumonia and 
13.9 for outpatient treated pneumonia (PCV7-I). In the study reassessing the cost-
effectiveness of the PCV7 programme (PCV7-II), we estimated the incidence of potentially 
pneumococcal pneumonia separately in secondary health care (inpatient and outpatient cases) 
and primary health care (outpatient cases). The number of pneumonia cases in secondary 
health care was extracted from the Hospital Discharge Register (2001–2006) with one of the 
following International Classification of Diseases 10th revision (ICD-10) codes for 
pneumonia codes as the first-listed diagnosis: 
̶ J13 Pneumonia due to Streptococcus pneumoniae,  
̶ J15.9 Bacterial pneumonia, unspecified, 
̶ J18.1 Lobar pneumonia, unspecified, 
̶ J18.8 Other pneumonia, organism unspecified, 
̶ J18.9 Pneumonia, unspecified 
The total incidence of potentially pneumococcal pneumonia in outpatient care was estimated 
by adding the age group -specific proportion of outpatient cases (191) to the incidence of 
inpatient cases in secondary health care estimated from the Hospital Discharge Register. The 
outpatient cases in primary health care were the difference between total outpatient cases and 
outpatient cases in secondary health care. The total outpatient cases in primary health care 
were further divided into age subgroups by the data retrieved from two health centres in 
Southern Finland (Tuusula 2001–2006 and Kangasala 2000–2006).   
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In the base-case, deaths from pneumonia were not included in the analysis in the first 
economic evaluation of the PCV7 programme (PCV7-I) and in cases aged 0–19 years in the 
second (PCV7-II) evaluation. In cases aged ≥20 years, the case fatality ratio for inpatient 
pneumococcal pneumonia was estimated from the Causes of Death statistics with ICD-10 
codes J13 and J18.1 (OSF, 1996–2005). The case fatality ratio increased from 0.04% to 1.3% 
among cases aged ≥20 years (PCV7-II).  
In both economic evaluations of the PCV7 programme, the incidence of AOM was estimated 
identically and only for children aged <5 year olds. In children aged 0 to 1 year olds, the 
incidence of all-cause AOM was taken from the Finnish Otitis Media (FinOM) Vaccine Trial 
(44). The incidence of 2-year-olds was calculated by assuming the incidence of 1-year-olds in 
the FinOM trial decreased by the same proportion as in a previous epidemiological study of 
AOM incidence in Finland (190) and the AOM incidences for children aged 3 to 4 years were 
calculated accordingly.  
The incidence of otological surgery procedures due to AOM was estimated from national 
population-based registry data covering procedures performed in public (Hospital Discharge 
Register) and private (Social Insurance Institution Register of Special Reimbursements) 
health care. We included in the analysis both tympanostomies and/or adenotomies (1996–
1999) in the first (PCV7-I) economic evaluation of the PCV7 programme and 
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4.2.1.2 Influenza-related disease outcomes in children (II) 
The incidence of influenza and influenza associated complications (pneumonia, sinusitis, 
AOM) were obtained from a prospective epidemiological cohort study of laboratory-
confirmed respiratory infections in children aged <14 years covering two influenza seasons 
(108). The influenza incidence per 1000 children was 179 for children aged <3 years old, 175 
for children aged 3–6 years old and 142 for children aged 7–13 years old. In corresponding 
age groups, AOM was diagnosed in 39.7%, 19.6% and 4.4% of the children and sinusitis in 
0.8%, 6.8% and 8.8% of the children with influenza, respectively. In addition, a severe illness 
case was defined as a laboratory-confirmed influenza case seeking care in the hospital 
emergency department (Turku University Hospital register, 1988–2004). A severe case was 
defined to be 2.3%, 1.3% 0.3% of the influenza cases in children aged 6 months to <1 years, 
aged 1–2 years and ≥3 years, respectively. We assumed no influenza-associated deaths to 
occur in children.  
4.2.1.3 HPV-related genital disease outcomes in women (III, IV) 
The incidences of cervical, vaginal, and vulvar cancer were estimated from the cancer 
notifications from the Finnish Cancer Registry (1999–2008). The incidences of 
adenocarcinoma in situ (AIS) and cervical intraepithelial neoplasia grade 3 (CIN3) were 
estimated from the Cancer Registry and Hospital Discharge Register data (2004–2008). Other 
cervical, vaginal, and vulvar intraepithelial neoplasia (CIN1–2, VaIN1–3, VIN1–3) cases 
were estimated from the Hospital Discharge Register data (2004–2008). The incidence of 
cases defined as minor cytological abnormalities were estimated using the Mass Screening 
Registry, the Hospital Discharge Register, the SII (Social Insurance Institution) register on 
Special Reimbursements, the Student Health Service Register, and the HUSLAB Pathology 
Laboratory Register (2004–2008). The incidence of external genital warts was estimated from 
the reimbursed prescriptions of podophyllotoxin or imiquimod in the SII Register of 
Prescribed Medicines (2004–2008). Imiquimod is also used for other dermatology diseases, 
mostly among older people. The age-specific pattern of podophyllotoxin and imiquimod use 
was similar in those aged <45 years. In older age groups, the imiquimod use started once 
more to increase while podophyllotoxin use continued to decrease. We extrapolated the 
prescriptions for imiquimod for external genital warts from its other use by applying a similar 
age-specific pattern of use to that of podophyllotoxin. 
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4.2.2 Cost analysis  
The cost analyses were performed from the health care provider perspective and, in economic 
evaluations of PCV7 (PCV7-I) and influenza (II) programmes in children, also from the 
societal perspective. In the first economic evaluation of PCV7 (PCV7-I) in the original 
publication, the base-case results were shown using the 3% discount rate. However, a 5% 
discount rate was recommended to be used in Finland when PCV7 was considered for 
inclusion into the NVP for the first (PCV7-I) and second (PCV7-II) time. Therefore, in this 
study the base-case results of both economic evaluations of the PCV7 programme are shown 
using the 5% discount rate for the future benefits and costs. We estimated the average use of 
health care services and assigned a monetary value (unit cost) to each service. The average 
health care cost per case included the management and treatment of the disease outcome.  
4.2.2.1 Use of health care services  
In the economic evaluations of PCV7 (PCV7-I) and influenza (II) vaccination programmes in 
children, registers, epidemiological studies, international scientific publications and expert 
interviews were used to assess the health care resource use due to disease outcomes. The 
assessment was derived from separate sources without using individual-level register data. In 
the economic re-evaluation of the PCV7 vaccination programme (PCV7-II), the use of health 
care resources in secondary health care was estimated from individual-level registry data 
linking each individual’s events within the register with the encrypted identity code.  
In the cost of illness study of HPV-related genital disease in women (III, IV), the use of 
health care resources in secondary health care, organised and opportunistic Pap tests by 
health care provider, and diagnostic and treatment procedures by private provider were 
estimated from individual-level registry data linking each individual’s events within and 
between the different registers with the unique identity code. Register-based individually 
linked data provided information that enabled identification of the whole treatment episode 
per woman and to classify the purpose (screening or follow-up) of the Pap tests taken outside 
the screening programme. The latter information was essential in estimating the coverage and 
frequency of Pap testing while taking into account tests taken both within and outside the 
organised programme. 
Pneumococcal-related disease outcomes 
The assumed health care resource use due to disease outcomes in the first economic 
evaluation of the PCV7 vaccination programme (PCV7-I) is shown in Table 4. The health 
care resource use due to post-meningitic hearing impairment was assessed using expert 
interviews. The risk of developing a hearing defect after pneumococcal meningitis was 
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In the economic re-evaluation of the PCV7 vaccination programme (PCV7-II), the average 
health care resource use in secondary health care due to IPD and pneumonia was estimated 
from data that included each individual identified with the disease outcome in the Hospital 
Discharge Register (2000–2006) with the appropriate ICD-10 code. Diagnosis indicating the 
most serious outcome determined the pneumococcal-related outcome of each case. 
Pneumococcal meningitis (G00.1) was considered to be the severest outcome, followed by 
pneumococcal bacteraemia (A40.3), potentially pneumococcal pneumonia (J13, J15.9, J18.1, 
J18.8, J18.9) being the least severe of these outcome categories. We used the encrypted 
identity code to identify each individual’s events in the register data, while hospitalisations 
and hospital outpatient visits were extracted with ICD-10 codes related to the pneumococcal 
disease in question. The health care resource use was estimated for 3 years (meningitis) or 
one year (other outcomes) after the onset of the disease. The average number of events per 
case per year was derived by dividing the total number of each event type by the total number 
of cases in the follow-up.  
The risk of sequelae after pneumococcal meningitis and the additional health care resource 
use due to neurologic sequelae in secondary health care was estimated from Hospital 
Discharge Register data with appropriate ICD-10 codes. Out of 255 cases of pneumococcal 
meningitis, 16% had an ICD-10 code referring to neurologic sequelae and 12% to hearing 
impairment. One in five of the cases that had a hearing impairment likewise had Cochlear 
implant surgery. Expert interviews were used to evaluate the additional lifetime health care 
resource use due to hearing impairment.  
The average number of physician visits per pneumonia case in primary health care was 
estimated from data retrieved from two health centres (Tuusula and Kangasala) in Southern 
Finland. The health care services and medication used due to AOM was obtained from a 
study that compared the treatment and management of AOM in the FinOM-study and in 
Porvoo health centre in Southern Finland (196). A case with tympanostomy tube was 
assumed to visit a physician twice before the otosurgical procedure. In both economic 
evaluations of PCV7 (PCV7-I, PCV7-II) we assumed that giving one dose of vaccine to a 
child takes 5 min of a nurse’s working time.  
Influenza related disease outcomes in children  
The average use of health care resources due to influenza was estimated using registers, 
published studies, and expert interviews (Table 5). Only cases that received medical attention 
were included in the analyses. The average number of physician visits per case for influenza 
and its complications was obtained from a prospective epidemiological cohort study of 
laboratory-confirmed respiratory infections in children (108). In the analysis, we did not vary 
the estimates for visits per case by age since either the estimates in different age groups were 
close to each other (AOM in children aged 6 months to <7 years) or there were too few cases 
to stratify the estimates by age (AOM in children aged ≥7 years and all other complications).  
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The hospitalization rate for severe illness cases (40%) was derived from virologically 
confirmed influenza cases in patients who sought medical care in the hospital emergency 
department in Turku University Hospital during 1988–2004. A follow-up visit was assumed 
to occur in all pneumonia cases and in 40% of the AOM cases. Bacterial infections were 
assumed to be treated with antibiotics. We estimated from the first economic evaluation of 
the PCV7 programme that 0.06 otosurgical procedures were performed per each episode of 
otitis media in children. The seasonal influenza vaccination is given in the autumn. Thus, 
unlike PCV7 it is not always given in a regular well-baby clinic visit. Thus, we assumed that 
giving one dose of influenza vaccine to a child takes 10 min of a nurse’s working time. 
Analogously we did not include in the analysis the pharmacotherapy of symptomatic 
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HPV-related genital disease outcomes in women 
The health-related events due to the management, treatment, and follow-up of the HPV 
disease outcome in question were extracted from the registers with the appropriate ICD-10 
codes (secondary health care), International Classification of Diseases for Oncology codes 
(cancer register notifications), Nordic Classification of Surgical Procedures codes (diagnostic 
and treatment procedures), and medical test (Pap test). The diagnosis indicating the most 
serious outcome determined the HPV-related outcome category of each individual. The HPV 
outcome categories were ranked in the following declining order of severity: cancer, AIS, 
CIN3, VaIN3, VIN3, CIN2, VaIN2, VIN2, CIN1, VaIN1, VIN1, minor cytological 
abnormalities and external genital warts. We used the unique personal identity code to link 
each individual’s (case) health-related events in the different registers. An index event was 
defined to occur at the time point when a woman was first time assigned the diagnosis that 
determined its outcome category. At the time point of the index event, the health-related 
events of each case were divided into 1-year pre- and post-diagnostic periods. We estimated 
the average number of each events (outpatient visits, inpatient hospitalizations, 
gynaecological procedures by private providers, follow-up Pap tests) per case by dividing the 
total number of each event type by the total number of cases in follow-up in the year of 
interest.  
The unique personal identity code was used to link the Pap tests taken within and outside the 
organised screening with the HPV-related events of a woman. Pap tests were classified by the 
purpose of the test. A Pap test was taken for screening purposes (screening test) or due to a 
previous abnormal cytological or histological finding (follow-up test). In the screening 
programme, both the purpose and the result of the test are registered. For tests taken outside 
the screening programme, neither purpose nor result of the test is registered except for the test 
results in the HUSLAB register. A test was considered to be a screening test if it did not fulfil 
any of the following criteria of a follow-up test:  
1. Test taken outside the organised screening within 30 months after an abnormal test in 
organised screening, 
2. Test taken within 15 months after an abnormal test result or within 10 months after a 
test with unknown result, 
3. Test taken within 15 months after a test with an unknown result in the student health 
service, 
4. Test obtained within 30 months after the first-listed diagnosis code or treatment 
procedure code indicating intraepithelial neoplasia, or at any time after the first 
cervical, vaginal, or vulvar cancer notification.  
We estimated the annual average number of Pap tests as well as the coverage and frequency 
of Pap testing by age and screening modality in Finland in 2004–8. The numbers of Pap tests 
were obtained from nationwide data with the exception of the public primary health care (not 
available) and secondary health care tests (incomplete) that were extrapolated from Helsinki 
region data. In addition, the Helsinki metropolitan region data were used in estimating the 
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overall coverage and frequency of Pap testing per woman for the 5-year period of 2004–8. 
The age of the woman in the coverage and frequency estimations was determined according 
to the year 2008 (index year). We included in the analyses all Pap tests for each woman that 
were carried out in 2004–2008 (i.e. during the preceding 5 years of the index year 2008). In 
assessing the age-specific coverage the denominator was calculated as the mean number of 
women at the corresponding age in year 2008, one year younger in 2007, two years younger 
in 2006, and so forth in the Helsinki metropolitan region in 2004–8. With such an average, 
we corrected the uneven age distribution, especially in young women due to the open cohort, 
accounting for the positive net migration in young women into the Helsinki region.   
4.2.2.2 Health care costs  
The sources used in estimating the unit costs is summarised in Table 6 and the main unit cost 
estimates in the economic evaluations of PCV7 and children's influenza vaccination 
programmes at the 2010 price level is summarised in Table 7. The unit costs for secondary 
health care were totally (PCV7-II, III, IV) or partially (II) estimated using individual-level 
cost accounting data from the Hospital District of Helsinki and Uusimaa in all other studies 
except the first economic evaluation of the PCV7 programme (PCV7-I). The differences in 
the unit costs in economic evaluations of PCV7 (PCV7-I, PCV7-II) are due to these different 
data sources. Other unit cost estimates were mainly taken from the widely used national 
pricelist for unit costs of health care in Finland (197-199). The unit cost of tympanostomy in 
private health care was obtained from a price comparison of private health care services 
(Finnish Consumer Agency 2003). We used retail prices without value-added tax as a cost of 
pharmacotherapy.  
  
   
51 
 
Table 6. Sources used in estimating the unit cost of care. Yes/No indicates whether or not the 
information was used in the study.  
PCV7-I PCV7-II Influenza HPV 
Publication year 2005 (I) Previously unpublished 2006 (II) 
2013 (III), 
2014 (IV) 
National pricelist for unit costs of health care in 
Finland (197, 198) (199) (198) (199) 
Primary health care 
Primary care physician visit Yes Yes Yes Yes 
Secondary health care 
Inpatient hospitalisation Yes No No No 
Outpatient visit Yes No Yes No 
Tympanostomy, public health care Yes No No N/A 
Private health care  
Physician visit, specialist Yes Yes No Yes 
Other costs 
The fully-burdened labour cost of a nurse Yes Yes Yes N/A 
Price comparison of private health care services 
(Finnish Consumer Agency 2003)     
Tympanostomy, private health care Yes Yes Yes N/A 
Individual-level cost accounting data from the 
Hospital District of Helsinki and Uusimaa     
Secondary health care 
Inpatient hospitalisation No Yes Yes Yes 
Outpatient visit No Yes No Yes 
Tympanostomy, public health care  No Yes Yes N/A 
 
N/A, not applicable 
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Table 7. The main unit cost estimates in economic evaluations of PCV7 and children's influenza 
vaccination programmes, euros at the 2010 price level 
 PCV7-I (I) PCV7-II PCV7-II 
Influenza 
(II) 
Target group 0–4y 0–4y 5+y 0.5–13y 
Secondary health care1     
Meningitis, inpatient hospitalisation 8250 7377 11 336 N/A 
Meningitis, outpatient visit, emergency department 247 696 896 N/A 
Meningitis, outpatient visit  240 194 330 N/A 
Neurologic sequelae of meningitis, inpatient 
hospitalisation N/A 2983 2710 N/A 
Neurologic sequelae of meningitis, outpatient visit, 
emergency department N/A 1131 493 N/A 
Neurologic sequelae of meningitis, outpatient visit  N/A 287 232 N/A 
Bacteraemia, inpatient hospitalisation 2532 1541 6138 N/A 
Bacteraemia, outpatient visit, emergency department 247 268 494 N/A 
Bacteraemia, outpatient visit  240 176 277 N/A 
Pneumonia, inpatient hospitalisation 2085 1548 4968 N/A 
Pneumonia, outpatient visit, emergency department 247 198 317 N/A 
Pneumonia, outpatient visit 240 159 215 N/A 
Influenza, inpatient hospitalization N/A N/A N/A 1868 
Outpatient visit, emergency department 253 
Tympanostomy, public health care  703 748 N/A 748 
Primary health care 
Routine visit to a primary care physician, no tests 71 68 68 70 
Primary care physician visit, includes tests, X-ray  71 129 129 125 
Visit to speech therapist 61 82 82 N/A 
Labour cost per hour, nurse 33 33 33 33 
Private health care  
Physician visit, Ear, nose and throat specialist, 
private health care 77 74 N/A 74 
Tympanostomy, private health care  758 800 N/A 800 
Costs associated with hearing impairment N/A 
Costs associated with a Cochlear implant, first year 59 501 41 940 37 023 
Costs associated with a Cochlear Implant, 
subsequent years 734 - 4863 142 - 13442 142 - 11762  
Costs associated with hearing aid, first year 5413 4746 2274 
Costs associated with hearing aid, subsequent years 367 - 4816 107 - 4746 107 - 3067 
Other costs 
Assumed vaccine price (EUR) per dose 60.7 52.3 N/A 2.8 
Cost of vaccine administration (EUR) per dose 2.01 2.76 N/A 3.85 
Average gross income of Finnish employees per day 208 N/A N/A 208 
Average travel cost per visit in primary health care 6.6 N/A N/A 6.6 
 
N/A, not applicable 
1Estimates are presented in broader age groups. In the analysis, estimates varied by 1-year age bands. 
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In the HPV study (III, IV), the average unit costs in secondary health care (hospitalizations 
and outpatient visits) were estimated from cost accounting data from the Hospital District of 
Helsinki and Uusimaa. The estimates included diagnostic and treatment procedures and were 
estimated for hospitalizations and outpatient visits by outcome and pre- and post-diagnostic 
periods. The unit cost of a Pap test in the organised screening programme was the mean price 
of the organised screening test in 5 university towns. The cost included the entire screening 
package: invitation letter, preparation and interpretation of the test, reply letter, registration, 
documentation and analysing the screening registry data. In the organised programme the Pap 
test is carried out by a nurse. Outside the organised programme the Pap test is taken during a 
physician visit. The cost of a Pap test taken outside the organised programme included the 
laboratory fees and half (tests with screening purpose) or all costs (test with follow-up 
purpose) incurred from the physician visit by the health care provider. Figure 3 summarises 
the main unit cost estimates for HPV-related genital disease outcomes.  
 
 
Figure 3. The main unit cost estimates in the HPV cost of illness study, euros at 2010 price level. (a) 
Pap-testing costs include the unit price for the test and half (tests with screening intention) or the 
whole (follow-up tests) prices of a visit to a physician. (b) Secondary health care costs. Average unit 
cost per hospitalisation or outpatient visit, estimates include diagnostic and treatment procedures (cost 
accounting data from the Hospital District of Helsinki and Uusimaa)   
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The average health care cost per case for a given outcome was derived by assigning the unit 
costs to the events. The cost per case included the costs of managing and treating the disease 
outcome for one or several years. If the health care costs were spread over several years, the 
cost per case was derived by summing up the estimated costs of the consecutive years. The 
years before diagnosis are referred to as pre-diagnostic years and the years after diagnosis as 
the post-diagnostic years.  
In the first economic evaluation of the PCV7 programme (PCV7-I) and the economic 
evaluation of the influenza programme (II), the cost per case was delimited to one post-
diagnostic year, with the exception of pneumococcal meningitis with hearing impairment. In 
the economic re-evaluation of the PCV7 programme (PCV7-II), the cost per case included the 
management and treatment costs of three post-diagnostic years (pneumococcal meningitis 
outcomes) or one post-diagnostic year (all other outcomes). The health care cost of the 
hearing impairment due to pneumococcal meningitis (PCV7-I, PCV7-II) was estimated for 
the lifetime. Cases in secondary health care were treated either as inpatient or outpatient. In 
the first economic evaluation of the PCV7 programme (PCV7-I), all cases of meningitis and 
bacteremia and 51% of pneumonia cases (191) were assumed to be treated as inpatients. In 
the economic re-evaluation (PCV7-II), all cases of meningitis, 92% cases of bacteremia, and 
60% of pneumonia cases were estimated to be treated as inpatients among children aged 0 to 
4 years (Health Care Register 2000–2006). Table 8 summarises the average total medical cost 
per case for pneumococcal- and influenza-related disease outcomes.  
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Table 8. Average undiscounted total medical cost per case1 of pneumococcal- and influenza-related 
disease outcomes at 2010 price level  
Pneumococcal-related disease outcomes 
PCV7-I (I) PCV7-II 
0–4y 0–4y 5–19y 20–64y 65+y 
Meningitis, no complications 9113 12 621 9005 22 628 18 516 
Meningitis with neurologic sequelae 9113 17 881 11 799 26 480 22 466 
Meningitis with hearing impairment 49 883 105 618 74 024 50 322 26 230 
Bacteremia  2849 1840 1805 8976 6487 
Pneumonia, secondary health care  1389 1285 1850 4817 4740 
Pneumonia, primary health care N/A 181 199 202 187 
AOM  119 108 N/A N/A N/A 
Tympanostomy 1027 935 N/A N/A N/A 
Adenotomy  1474 N/A N/A N/A N/A 
Tympanostomy and adenotomy2  1522 N/A N/A N/A N/A 
Influenza-related disease outcomes (II) 
  0–4y 5–13y   
Influenza with      
no complications  70 70   
acute otitis media   223 242   
outpatient pneumonia  245 245   
sinusitis   82 82   
severe, outpatient care  323 323   
severe, inpatient care  2368 1977   
 
1Estimates in this table are presented in broader age groups. In the analysis, estimates varied by 1-year age 
bands. 
2Simultaneously done  
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In the cost of illness study of HPV, the average cost per cancer and dysplasia case included 3 
pre-diagnostic years and 9 post-diagnostic years. In other HPV-related outcomes the 
corresponding costs included 4 (minor cytological abnormalities) or 5 (external genital warts) 
post-diagnostic years (Figure 4).  
 
 
Figure 4. Average undiscounted cost per case of HPV-related disease outcomes at the 2010 price level  
4.2.2.3 Other costs 
In the first economic evaluation of the PCV7 programme (PCV7-I) and the influenza 
programme (II) we estimated the productivity costs due to parental work absenteeism and the 
travel costs of visits to primary or secondary care due to illness. Parental work absenteeism 
was estimated only for children <10 year olds, since Finland has a system of paid temporary 
care leave for one of the parents for a maximum of 4 days when a child <10 years of age 
suddenly gets ill. Parental work absenteeism was assumed to occur for under school-aged 
children attending out-of-home day care (200) and for school-aged children whose mothers 
participated in the labour market (OSF). In the economic evaluation of the influenza 
vaccination programme, we also estimated the parental work absenteeism and travel costs for 
taking the child to the site of vaccination.  
Two prospective epidemiological studies were used to obtain the duration of parental absence 
due to influenza-related outcomes (108) and due to AOM (201). In the first economic 
evaluation of PCV7 (PCV7-I), we assumed the parental work absenteeism to be the same in 
outpatient pneumonia as in AOM (1.3 days per episode). For inpatient cases (meningitis 9.9 
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days, bacteremia 3.5 days, and pneumonia 3.3 days) we used the average number of inpatient 
days as an approximation of the duration of parental work absenteeism. In the first economic 
evaluation of PCV7 (PCV7-I), in addition, we evaluated the lost earnings due to premature 
death (IPD) and morbidity (hearing impairment due to pneumococcal meningitis).  
The average gross income of Finnish employees was used to value production losses. 
Average travel cost per visit in primary health care or to an emergency department was 
obtained from a Finnish study (202).  
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4.2.3 Health-related Quality-Adjusted Life-Years (QALYs) lost for potentially 
vaccine-preventable disease outcomes   
Estimates of the impact of the disease outcomes on the health-related quality of life were 
mainly obtained from the literature (Table 9). Finnish estimates were available only for a few 
conditions. The QALY loss following the hearing impairment (unpublished estimate) due to 
pneumococcal meningitis and post-treatment cancer survivors (203) were obtained from the 
Finnish Health 2000 Survey (204), which is a national health survey carried out in Finland in 
2000–2001. The QALY loss following an abnormal cervical cytology was obtained from the 
prospective arm of an observational study of women referred for colposcopy at the Helsinki 
University Hospital in 2007–2010 (205).  
The QALY loss estimates for childhood disease outcomes are particularly scarce. The natural 
development in growth and cognitive and functional abilities of the child, among other 
things, make measuring the health-related quality of life for the child more complex than that 
of adults (206). Thus, with the exception of AOM (207), we used QALY loss estimates of 
adults for all other pneumococcal disease outcomes in children. Although a health-related 
quality of life was not assessed in the original publication (II), in this study the QALY loss 
for influenza illness was obtained from a study assessing the impact of pandemic influenza on 
health-related quality of life in 7 regions of England (208). In the influenza-like illness 
control group, 30% were children younger than 16 years. The expected life years lost due to 
death from IPD and cervical, vaginal, and vulvar cancers were estimated from the age- and 
gender-specific life expectancy of the Finnish population (OSF) under the assumption that the 
case fatalities would have had an average life expectancy and all life years were lived in 
perfect health.   
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Table 9. QALY loss per case due to disease outcomes  
QALY loss per case Reference 
Pneumococcal-related disease outcomes (PCV7-I, PCV7-II)   
Bacteraemia 0.006 Assumption 
Meningitis 0.006 Assumption 
Profoundly deaf (first y)1 0.216 (204) 
Profoundly deaf (subsequent y)1 0.054 (204) 
Needs hearing-aid1 0.054 (204) 
Moderate hearing loss1 0.054 (204) 
Pneumonia, outpatient 0.004 (209) 
Pneumonia, inpatient 0.006 (209) 
AOM 0.005 (207) 
Tympanostomy and/or adenotomy  0.005 Assumption 
Influenza-related disease outcomes (II) 0.0075 (208) 
HPV-related disease outcomes (III, IV) 
Cervical intraepithelial neoplasia (CIN1, CIN2, CIN3)1 0.0177 (205) 
Vaginal intraepithelial neoplasia (VaIN1, VaIN2, VaIN3)1 0.0177 (205) 
Vulvar intraepithelial neoplasia (VIN1, VIN2, VIN3)1 0.0177 (205) 
Minor cytological abnormalities 
with only follow-up Pap tests1 0.004 (205) 
with cervical biopsy1 0.004 (205) 
with surgical procedure1 0.0177 (205) 
Cervical, vaginal, and vulvar cancer2 
Stage I 
Year of treatment 0.32 (210) 
2nd - 5th post-treatment year 0.03 (182) 
6th + post-treatment years 0.018 (203) 
Stage II 
Year of treatment 0.44 (210) 
2nd - 5th post-treatment year 0.1 (182) 
6th + post-treatment years 0.1 (182) 
Stage III – IV 
Year of treatment 0.52 (210) 
2nd - 5th post-treatment year 0.38 (182) 
6th + post-treatment years 0.38 (182) 
Genital warts 0.039 (211) 
1 QALY loss measured by the 15D other values measured by EQ-5D 
2 Mean loss of QALYs for cervical cancer was adjusted for the age group distribution of each cancer and the 
respective survival rates 
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4.3 Effectiveness of the PCV7 programme 
In both economic evaluations of the PCV7 programme (PCV7-I, PCV7-II), the effectiveness 
of the programme on the vaccinated individuals was estimated using the vaccine efficacy 
estimates from the Northern California Kaiser Permanente (NCKP) vaccine trial (IPD, 
pneumonia, otologic surgical procedures) and the Finnish Otitis Media (FinOM) vaccine trial 
(AOM) (44, 54, 55). Table 10 summarises the vaccine efficacy estimates and the references. 
We assumed that the serotype distribution in IPD were comparable in Finland and Northern 
California according to the reported serotype distributions and made no serotype adjustments 
to the vaccine effectiveness estimates (193, 212, 213).  
In the first economic evaluation of the PCV7 programme (PCV7-I), we used the per-protocol 
efficacy estimate for AOM (44) and the intention-to-treat estimates for all other outcomes 
(54, 55). The per-protocol estimate for AOM (6%) in the FinOM trial (44) was used since it 
was almost the same as the intention-to-treat estimate in the NCKP trial (6.4%) (54). In the 
economic re-evaluation of the PCV7 programme (PCV7-II), we used the per-protocol 
efficacy estimate for all-cause pneumonia and the intention-to-treat estimates for all other 
outcomes (54, 55, 214). For all-cause pneumonia (pneumonia treated in primary health care), 
the per-protocol estimate was lower than the intention-to-treat estimate (55). The former was 
selected because we wanted to be especially conservative.  
AOM is known to be a common complication of upper respiratory tract infection (Heikkinen 
2003). The vaccine does not prevent the preceding upper respiratory infection but it prevents 
some of the physician visits due to it. In other words, the child might seek medical care for 
the upper respiratory infection even though the episode of AOM is prevented. Thus, we 
assumed that the vaccine programme reduces all AOM-related sick visits to physicians as 
well as antibiotic prescribing by 4% among vaccinated individuals (214). In both studies, we 
assumed that the direct vaccine protection lasted for 5 years.  
In the first economic evaluation of the PCV7 vaccination programme (PCV7-I), no indirect 
herd effects of the vaccination programme on the unvaccinated population were taken into 
account and in the base case analysis, a four-dose programme was assumed according to the 
manufacturer’s recommendation at the time. In the economic re-evaluation of the PCV7 
vaccination programme (PCV7-II), we considered three scenarios. In the vaccinated effects 
scenario, only the effects of the vaccination programme on the vaccinated individuals were 
included in the analysis. In the indirect effects scenarios, the indirect herd effects on IPD 
(scenario A) and on both IPD and pneumonia (scenario B) on the unvaccinated population 
were also included in the analysis. Vaccine effectiveness after the first dose for the 
vaccinated was derived from a study that investigated the effectiveness of incomplete 
schedules of the vaccination programme against IPD (215). In this study the effectiveness of 
the vaccination programme against IPD after the first, second and third dose was 73%, 96% 
and 95%, respectively. Thus, we assumed the reduction after the first dose to be 76.8% 
(73/95) of the used estimate for each pneumococcal disease outcome. After the second dose, 
we assumed no reduction in the used estimate.  
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In the economic re-evaluation, the impact of the indirect herd effects of the PCV7 vaccination 
programme on the cost-effectiveness was investigated with static scenario analysis. In 
addition to the total effect on the vaccinated individuals, we assumed the vaccination 
programme to reduce 20% of the IPD cases among the unvaccinated population aged ≥5 
years (indirect effects scenario A) or 20% of the IPD and 4% of the pneumonia cases treated 
in secondary health care in the same population (indirect effects scenario B). At the time the 
analysis was conducted the post-vaccination estimates from the USA were the only source for 
the indirect effect estimate. The assumed reduction in IPD among the unvaccinated was 
roughly based on the first post-vaccination year estimates in the USA where the rate of IPD 
decreased 32% in those aged 20–39 years, 8% in those aged 40–64 years, and 18% in those 
aged ≥65 years (68). The indirect herd effect on pneumonia on the unvaccinated population 
was assumed to be almost half of the total effect on the vaccinated. The reduction in the 
unvaccinated population was assumed to consist of both the reduction in vaccine-type disease 
induced by herd protection and the increase in non-vaccine-type disease due to replacement.  
 
Table 10. The vaccine efficacy estimates against pneumococcal disease outcomes used in evaluating 
the effect of vaccination programme on the vaccinated individuals 
PCV7-I PCV7-II Reference 
All IPD 89.1 89.1 (54) 
Pneumonia 
Clinical pneumonia with a positive radiograph  17.7 N/A (55) 
Clinical pneumonia and radiograph obtained1 N/A 8.9 (55) 
All clinical pneumonia2, 3 N/A 4.3 (55) 
All AOM3 6.0 N/A (44) 
AOM related visits to physician N/A 4.0 (214) 
Otologic surgical procedures   20.3 20.3 (54) 
 
N/A, not applicable 
1Pneumonia treated in secondary health care 
2Pneumonia treated in primary health care 
3 Per-protocol estimates, intention-to-treat estimates for all other outcomes 
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4.4 Effectiveness of influenza vaccination programme in children 
In the base case, we assumed the inactivated influenza vaccination programme to reduce 80% 
of the influenza cases in vaccinated individuals (120, 216). We assumed no indirect herd 
effect of the influenza vaccination programme on unvaccinated individuals.  
4.5 Sensitivity analysis in the economic evaluations of PCV7 and 
influenza vaccination programmes  
In the economic evaluations of the PCV7 programme (PCV7-I, PCV7-II), we investigated the 
effects of variation in the key parameters of the model in the scenario analyses. In the 
economic re-evaluation of the PCV7 vaccination programme (PCV7-II), a multivariate 
probabilistic sensitivity analysis was conducted from the health care payer perspective for the 
indirect effects scenarios A and B. The vaccine price, discount rate, and vaccine effectiveness 
estimates were held constant and the other parameters of the model were allowed to change 
within their specified ranges (Table 11). Since less severe IPD cases were assumed to be 
under-detected in Finland, the base case value was assumed in the sensitivity analysis to be 
the minimum value. The parameter of the IPD incidence ranged from the base case value to 
double the base case. The costs and QALY-losses of pneumococcal disease outcomes for the 
unvaccinated and vaccinated cohort were simulated 15 000 times. An ICER was calculated 
for each re-calculated mean values for costs and QALY-losses. The results are plotted on a 
cost-effectiveness plane and associated cost-effectiveness acceptability curve. The given 
distributions of input parameters were mainly based on data and if no data were available we 
defined a uniform distribution.  
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Table 11. Distributions used in the probabilistic sensitivity analysis. SD refers to the standard 
deviation of the respective log-normal distribution. Mean values of the parameters are listed in Tables 
3, 8 and 9.  
 Distribution Range SD SD SD SD 
0–4y 5–19y 20–64y 65+y 
Incidence rate 
Meningitis Uniform 0 to +100% 
Bacteraemia Uniform 0 to +100% 
Pneumonia, secondary health care Log-normal 0.0244 0.0263 0.0119 0.0097 
Pneumonia, primary health care Log-normal 0.0283 0.0198 0.0136 0.0162 
AOM  Log-normal 0.0020 
Tympanostomy Uniform ± 20 % 
Sequelae after pneumococcal disease 
outcomes       
Mortality in IPD Log-normal 2.9252 1.7177 0.1537 0.1485 
Mortality in pneumonia Log-normal 2.2361 1.8257 0.1547 0.1322 
Meningitis, neurologic sequelae Uniform ± 20 % 
Meningitis, hearing impairment Uniform ± 20 % 
Cost (EUR) per case 
Meningitis, no complication  Log-normal 12 204 9205 27 572 30 069 
Meningitis, neurologic sequelae Log-normal 7552 2277 8390 7767 
Meningitis, hearing impairment Uniform ± 20 % 
Bacteraemia Log-normal  2041 2053 14 875 14 026 
Pneumonia, secondary health care Log normal  2473 2491 17 133 18 629 
Pneumonia, primary health care Uniform ± 20 % 
AOM Uniform ± 20 % 
Tympanostomy Uniform ± 20 % 
QALY loss / case by disease outcome Uniform ± 20 %* 
 
Estimates in this table are presented in broader age groups. In the analysis, estimates varied by 1-year age bands.  
* Parameter was varied separately for each outcome.  
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In the economic evaluation of the influenza vaccination programme in children, we 
conducted several univariate sensitivity analyses, for example, on assumed vaccine efficacy 
and cost per dose. We used probabilistic sensitivity analysis to assess the effects of 
uncertainties in disease probabilities and in disease costs. Dirichlet distributions with 
Dirichlet parameter values set equal to the observed disease counts (as obtained from data 
(108)) were applied to form uncertainty distributions for the age-specific probabilities of 
different influenza-related disease outcomes. For each outcome-related cost, a lognormal 
density was formed s.t. 90% of the probability mass was assigned within the ± 60% range 
with respect to the base value. For costs that varied with age, simulated values were adjusted 
according to the proportions in the age-specific base values. The vaccine price was held fixed 
and the costs were simulated 10 000 times. 
  
   
65 
 
5 Results  
5.1 Current burden and costs of diseases potentially preventable 
by vaccinations  
The estimated annual burden and costs of pneumococcal-, influenza- and HPV-related 
disease outcomes before the implementation of the vaccination programmes are shown in 
Table 12. The pneumococcal-related disease burden was estimated in children aged 0–4 years 
in the first economic evaluation of the PCV7 programme (PCV7-I) and in all age groups in 
the economic re-evaluation of the PCV7 vaccination programme (PCV7-II). The influenza-
related burden of disease was estimated in children aged 0.5–13 years (II) and HPV-related in 
women aged ≥15 years (III, IV).  
5.1.1 Number of cases  
In children aged 0–4 years, there were estimated to be annually 69 IPD cases in the first 
economic evaluation of the PCV7 programme (PCV7-I) and 101 IPD cases in the economic 
re-evaluation (PCV7-II). The corresponding numbers for potentially pneumococcal 
pneumonia were 8165 and 2966, respectively. The difference in IPD cases was due to 
different calendar years the data were retrieved from and, in pneumonia cases, due to 
different data sources. In both economic evaluations of the PCV7 programme, 250 000 
episodes of AOM due to all causative pathogens were estimated to occur in children aged 0–4 
years. In the economic re-evaluation of the PCV7 programme (PCV7-II), of the annual 688 
cases of IPD and 34 897 cases of potentially pneumococcal pneumonia in all age groups, 
children aged 0–4 years accounted for 101 (15%) and 2966 (8%) cases, respectively. The all-
cause AOM cases were estimated only for children aged <5 years old.  
Without the vaccination programme, in children aged 6 months to 13 years, there were 
estimated to be 121 885 cases of symptomatic influenza annually, corresponding to an annual 
attack rate of 15%. These children had as a complication of influenza 18 076 cases of acute 
otitis media, 4 572 cases of sinusitis and 2 474 cases of outpatient pneumonia.   
Before the anticipated effects of the vaccination programme, there are annually on average 
153 cervical, 16 vaginal and 72 vulvar cancer cases in Finland. An average of 1033 new cases 
of CIN3/AIS, 1865 new cases of CIN1-2 and 34 400 new cases of minor cytological 
abnormalities are detected annually. Annually almost 4000 women receive medical care due 
to external genital warts.  
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An annual average of 446 000 Pap tests are carried out for screening purposes, of which 
177 000 (40%) are carried out in the organised programme, 24 000 (5%) in secondary health 
care and 244 000 (55%) as opportunistic tests. In addition, there are 84 000 Pap tests carried 
out as a follow-up of previously detected cervical abnormalities.  
5.1.2 Life-years and QALYs lost 
Approximately one child aged 0–4 years was estimated to die due to IPD every year (PCV7-I, 
PCV7-II). In all age groups, there were estimated to be an average of 219 deaths due to IPD 
and potentially pneumococcal pneumonia, corresponding to 3 421 estimated undiscounted 
life-years lost (PCV7-II). Of the estimated annual 94 deaths and 1737 life-years lost due to 
IPD, children aged 0–4 years accounted for one (1.5%) of the death cases and 111 (6%) of 
the life-years lost. We assumed no influenza- associated deaths to occur in children (II). An 
annual average of 56, 12 and 30 female deaths were due to cervical, vaginal, and vulvar 
cancer corresponded to 993, 127 and 346 estimated undiscounted life years lost, respectively 
(III).   
In children aged 0–4 years, the estimated potentially pneumococcal attributable QALYs lost 
were 1446 and 1435 in the first (PCV7-I) and second (PCV7-II) economic evaluation of the 
PCV7 programme. In children aged 0–4 years, all-cause AOM accounted for 91% of all 
pneumococcal attributable QALYs lost (PCV7-I, PCV7-II). In all age groups, 3421 (70%) of 
the total 4900 undiscounted QALYs lost were life-years lost due to pneumococcal-related 
deaths (PCV7-II). Of the estimated annual 914 non-fatal QALYs lost due to influenza-related 
disease outcomes in children aged 0.5–13 years, <3 year olds and <5 year olds accounted for 
190 (21%) and 338 (37%), respectively. Life-years lost accounted for 1466 (62%) of the 2368 
annual undiscounted QALYs lost due to HPV-related disease outcomes in women.   
5.1.3 Health care provider costs 
In children aged 0–4 years, the estimated health care costs were EUR 57.4 million in the first 
economic evaluation of the PCV7 programme (PCV7-I) and EUR 39.3 million in the 
economic re-evaluation (PCV7-II). The lower estimated health care costs in the re-evaluation 
were due to a lower incidence of pneumonia and the exclusion of adenotomies from the 
analysis. Of these estimated health care costs, IPD accounted for 0.5% and 1%, pneumonia 
21% and 6% and all-cause AOM 79% and 93% in the first and second evaluation, 
respectively. In the economic re-evaluation in all age groups, the estimated annual health care 
costs of IPD without the vaccination programme were EUR 5.0 million and of potentially 
pneumococcal pneumonia EUR 98.6 million. The costs of all-cause AOM were estimated to 
be EUR 36.6 million in children aged 0–4 years.  
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In children aged 6 months to 13 years, the estimated health care costs of influenza-associated 
outcomes were EUR 13.0 million, of which the costs of primary health care visits of 
uncomplicated cases accounted for EUR 6.7 million (52%) and the costs of AOM accounted 
for EUR 4.3 million (33%) (II). In children aged 6 months to 4 years the costs of AOM 
accounted for EUR 3.5 million (54%) of the total health care costs (EUR 6.5 million). 
The estimated annual health care costs of HPV-related genital disease outcomes in women 
were EUR 22.3 million, of which the management and treatment of detected cases of CIN 
and minor cytological abnormalities accounted for EUR 15.5 million (69%) (III). The annual 
cost of Pap tests taken for screening purposes was EUR 22.4 million of which EUR 5.0 
million (22%) were due to tests taken in organised screening, EUR 1.5 million (7%) in 
secondary health care and EUR 15.9 million (71%) in opportunistic screening (IV).  
5.1.4 Other costs 
We estimated the travel and productivity costs of the caregiver from illness in children in the 
first economic evaluation of the PCV7 programme (PCV7-I) and in the economic evaluation 
of the influenza programme (II). In addition, in the economic evaluation of the influenza 
vaccination programme we estimated the corresponding costs of taking the child to the site of 
vaccination.  
In children aged 0–4 years, the estimated annual travel costs due to pneumococcal-related 
disease outcomes were EUR 2.3 million. The estimated annual productivity costs due to 
parental work absenteeism were EUR 19.9 million and due to hearing impairment EUR 0.02 
million.  
Travel costs due to influenza illness were EUR 0.4 million in children aged 0.5–4 years and 
EUR 0.6 million in children aged 5–13 years. In corresponding age groups, the travel costs 
due to influenza vaccination were EUR 1.5 million and EUR 3.0 million, respectively.  
Productivity costs of parental work absenteeism due to influenza illness in children aged 0.5–
4 years were EUR 10.9 million and in children aged 5–13 years EUR 23.0 million. In 
corresponding age groups, the productivity costs due to influenza vaccination were EUR 2.2 
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5.2 Economic evaluation of pneumococcal conjugate vaccination 
programme  
The results of the economic evaluations of the PCV7 programme (PCV7-I, PCV7-II) from 
the health care payer perspective with base-case parameters are shown in Table 13. All costs 
are presented at the 2010 price level using a 5% discount rate for future benefits and costs 
according to the recommendations at the time these studies were conducted.  
5.2.1 Reduction in the burden of disease due to the vaccination programme 
In children aged 0–4 years, when taking into account only the direct effect of the vaccination 
programme on the vaccinated 0–4-year-olds, the vaccination programme was estimated to 
result in 108.5 QALYs gained annually in the first economic evaluation of the PCV7 
programme (PCV7-I) and 79.3 QALYs gained in the corresponding ‘vaccinated effects 
scenario’ of the economic re-evaluation (PCV7-II). In the economic re-evaluation, we 
estimated the PCV7 programme to prevent fewer pneumonia and AOM cases compared to 
the first evaluation since we applied lower vaccine effectiveness estimates for both 
pneumonia and AOM and estimating lower incidence rate for pneumonia. In children aged 0–
4 years, the PCV7 programme was estimated to prevent an annual average of 0.9 and 1.2 IPD 
deaths in the first (PCV7-I) and second (PCV7-II) economic evaluation corresponding to 17.2 
and 23.7 discounted life-years gained, respectively.  
In the economic re-evaluation of the PCV7 vaccination programme (PCV7-II), we estimated 
that the PCV7 programme would indirectly prevent annually 117 IPD cases and 19 IPD 
deaths in the ‘Indirect effects scenario A and B’ and additionally 818 pneumonia cases and 5 
pneumonia deaths in the ‘Indirect effects scenario B’. When taking into account both the 
direct and indirect herd effects of the PCV7 vaccination programme the vaccination 
programme was estimated to result annually in 276 QALYs gained and 220 life-years gained 
in the ‘indirect effects scenario A’ and 324 QALYs gained and 263 life-years gained in the 
‘indirect effects scenario B’.  
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5.2.2 Cost savings and cost-effectiveness from the health care provider 
perspective 
In children aged 0–4 years, the vaccination programme was estimated to save annually 
EUR 7.2 million in medical costs in the first economic evaluation of the PCV7 programme 
and EUR 3.0 million in the economic re-evaluation (Table 13). In the re-evaluation (PCV7-
II), taking into account the direct and indirect herd effects of the vaccination programme, we 
estimated a saving annually of in total EUR 4.0 million in the ‘Indirect effects scenario A’ 
and EUR 7.7 million in the ‘Indirect effects scenario B’. The cost of vaccinating a birth 
cohort was estimated to be EUR 13.1 and EUR 9.7 million in the first (PCV7-I) and second 
(PCV7-II) economic evaluations, respectively.  
When taking into account only the direct effect of the vaccination programme the estimated 
discounted cost per QALY gained was EUR 54 576 in the first evaluation and EUR 83 759 in 
the economic re-evaluation. Correspondingly, the cost per life-year gained was EUR 345 027 
and EUR 279 496. When taking into account the estimated direct and indirect herd effects on 
IPD (scenario A) of the vaccination programme, the cost per QALY gained was EUR 20 558 
and the cost per life-year gained was EUR 25 839 (PCV7-II). When taking into account the 
estimated direct and indirect herd effects on IPD and pneumonia (scenario B), the cost per 
QALY gained reduced to EUR 5983 and cost per life-year gained to EUR 7360. All estimates 
for cost-effectiveness ratios are presented from the health care provider perspective. 
5.2.3 Cost savings and cost-effectiveness from the societal perspective 
In the first evaluation of the PCV7 vaccination programme (PCV7-I), we estimated the 
reduction in the pneumococcal-related travel costs to be EUR 0.17 million and in productivity 
costs EUR 1.52 million (EUR 1.5 million and EUR 0.02 million due to, respectively, parental 
work absenteeism and hearing impairment) in children aged 0–4 years. From the societal 
perspective, the estimated discounted cost per QALY gained was EUR 39 121 and cost per 
life-year gained was EUR 247 323. Unlike in the original publication (I), the results from the 
societal perspective presented here do not include the productivity costs due to averted 
mortality in order to avoid double counting the mortality costs, as the gain in the life-years 
already manifests the mortality costs in the denominator of the ratio.  
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Table 13. Results of the economic evaluations of the PCV7 programme. Estimated annual outcomes 
prevented and health care costs saved by the vaccination programme versus no vaccination and 
incremental cost-effectiveness ratios (ICERs). Costs and benefits discounted at a 5% discount rate. 
Health care payer perspective. All costs presented at the 2010 price level. 









Birth cohort / Vaccination 
coverage 
57 574 / 
100% 58 000 / 97% 
  
Outcomes prevented     
Pnc meningitis 4 3 7 7 
Pnc bacteraemia 58 81 194 194 
Pneumonia 1445 194 194 1012 
All-cause AOM  14 982 9631 9631 9631 
IPD deaths 0.9 1.2 20 20 
Pneumonia deaths N/A N/A N/A 5 
Life-years gained 17.2 23.7 219.8 263.2 
QALYs gained, total 108.5 79.0 276.3 323.7 
IPD 19.0 24.5 221.8 221.8 
Pneumonia 6.6 0.8 0.8 48.3 
All-cause AOM  82.9 53.6 53.6 53.6 
Treatment costs saved 7 197 610 3 048 425 3 984 297 7 726 551 
IPD 242 766 197 673 1 133 542 1 133 542 
Pneumonia 1 982 224 175 539 175 539 3 917 794 
All-cause AOM  4 972 619 2 675 215 2 675 215 2 675 215 
Total direct vaccination costs -13 119 688 -9 663 536 -9 663 536 -9 663 536 
Administration costs  -458 138 -559 335 -559 335 -559 335 
Vaccine purchase4  -12 661 549 -9 104 202 -9 104 202 -9 104 202 
Total health care costs -5 922 078 -6 615 108 -5 679 239 -1 936 985 
Cost / QALY gained 54 576 83 759 20 558 5983 
Cost / Life-years gained 345 027 279 496 25 839 7360 
 
N/A, not applicable 
1Only direct effect of the vaccination programme on vaccinated individuals was assumed.  
2Direct effect on the vaccinated and 20% reduction in IPD among unvaccinated population aged 5 years and 
older was assumed. 
3Direct effect on the vaccinated and 20% reduction in IPD and 4% in pneumonia cases treated in secondary 
health care among unvaccinated population aged 5 years and older was assumed. 
4Assumed vaccine price per dose EUR 60.7 in PCV7-I and EUR 52.3 in PCV7-II  
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5.2.4 Sensitivity analysis  
The results of the economic evaluations of the PCV7 vaccination programme with different 
discount rates and half of the price in the base-case are shown in the Table 14. The discount 
rate influences the results of the cost-effectiveness analysis mostly by the impact on benefits 
(life-years gained). When only taking into account the direct effect of the vaccination 
programme and a vaccine price of EUR 25 per dose, the vaccination programme was cost 
saving in the first economic evaluation (PCV7-I) and the cost per QALY decreased to 
EUR 25 462 in the economic re-evaluation (PCV7-II) from the health care provider 
perspective.  
In the sensitivity analysis, we also investigated the impact of a lower indirect herd effect in 
IPD on the base case results (Indirect effects scenario A). When we assumed only a 10% or 
5% reduction in IPD in unvaccinated population aged 5 years and older, the cost per QALY 
increased from EUR 20 490 to EUR 34 566 or EUR 49 631, respectively.  
 
Table 14. Results of the economic evaluation of the PCV7 vaccination programme in different 
discount rates from the health care provider perspective. All costs are presented at the 2010 price 
level.  








Cost / QALY gained 
Discount rate 5%, base case 54 576 83 759 20 558 5983 
Discount rate 3% 45 875 70 098 17 044 4810 
Discount rate 0% 29 256 41 807 11 295 3027 
Vaccine price EUR 25 / dose Cost saving 25 462 3891 Cost saving 
Cost / Life-year gained 
Discount rate 5%, base case  345 027 279 496 25 839 7360 
Discount rate 3% 211 087 182 579 20 750 5752 
Discount rate 0% 72 750 103 900 86 322 24 947 
Vaccine price EUR 25 / dose Cost saving 84 963 4891 Cost saving 
 
1Only direct effect in vaccinated individuals of the vaccination programme was assumed.  
2Direct effect to the vaccinated and 20% reduction in IPD in unvaccinated population aged 5 years and older 
was assumed 
3Direct effect to the vaccinated and 20% reduction in IPD and 4% in pneumonia cases treated in secondary 
health care in unvaccinated population aged 5 years and older was assumed. 
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In the second economic evaluation of PCV7 vaccination programme (PCV7-II), we 
conducted a multivariate sensitivity analysis from the health care payer perspective for the 
indirect effects scenarios A and B versus no vaccination. The costs and QALY-losses of 
pneumococcal disease outcomes for the unvaccinated and vaccinated cohort were simulated 
15 000 times. In the cost-effectiveness plane (Figure 5), points below the red full line 
represent simulations in which the PCV7 vaccination programme was a cost-effective 
alternative at an assumed threshold of EUR 20 000 per QALY gained. The cost-effectiveness 
acceptability curves in Figure 6 were derived from the joint distribution of incremental costs 
and effects shown in Figure 5. The curve shows that the indirect effects scenario A (assuming 
direct effect to the vaccinated and 20% reduction in IPD in unvaccinated population aged ≥5 
years) was cost-effective versus no vaccination in nearly 100% of simulations at the 
willingness to pay threshold of EUR 20 000 per QALY gained.   
 
 
Figure 5. The Cost-effectiveness plane for incremental costs and effects of ‘Indirect effects scenario 
A’ and ‘Indirect effects scenario B’ versus no vaccination. EUR 20 000 per QALY gained threshold 
line indicated with the red line. Health care costs are presented at the 2010 price level and costs and 
benefits discounted at a 5% discount rate. Indirect effects scenario A: assuming a direct effect to the 
vaccinated and a 20% reduction in IPD in unvaccinated population aged ≥5 years. Indirect effects 
scenario B: assuming direct effect on the vaccinated and a 20% reduction in IPD and 4% in 
pneumonia cases treated in secondary health care in the unvaccinated population aged ≥5 years.  




Figure 6. The cost-effectiveness acceptability curves derived from the joint density of incremental 
costs and incremental effects (QALYs gained) for the PCV7 vaccination programme. ‘Indirect effects 
scenario A’ and ‘Indirect effects scenario B’ were compared to no vaccination scenario from the 
health care payer perspective. Health care costs are presented at the 2010 price level and costs and 
benefits discounted at 5% discount rate. Indirect effects scenario A: assuming direct effect to the 
vaccinated and 20% reduction in IPD in unvaccinated population aged ≥5 years. Indirect effects 
scenario B: assuming a direct effect to the vaccinated and a 20% reduction in IPD and 4% in 






























Willingness to pay for an additional QALY (€)
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5.3 Economic evaluation of influenza vaccination programme 
among healthy children 
When the vaccine effectiveness was assumed to be 80% and the vaccination coverage 100%, 
a vaccination programme targeted to children aged 0.5–4 years prevented 36 069 cases of 
influenza corresponding to 271 QALYs gained and EUR 5.2 million medical costs saved 
(Table 15). In this age group influenza cases with AOM accounted for 33% (11 915) of the 
cases prevented and 54% (EUR 2.8 million) of the treatment costs saved. In children aged 5–
13 years, influenza cases without complication accounted for 89% of the cases prevented and 
74% of the treatment costs saved. From the health care provider perspective, the vaccination 
programme was cost saving in children aged 0.5–13 years.  
Under base case assumptions, we estimated the increase in the influenza and influenza 
vaccination-related travel costs to be EUR 1.3 million and the reduction in productivity costs 
to EUR 5.9 million in children aged 0.5–4 years. The corresponding costs were EUR 2.9 
million and EUR 7.3 million in children aged 5–13 years, respectively. The travel costs of 
taking the child to the site of vaccination exceeded the travel costs related to influenza illness. 
The societal perspective, furthermore, increased the savings gained from the vaccination 
programme.  
In each age group, the savings exceeded the cost of the vaccination programme (remained 
cost-saving) with a vaccine efficacy of 60% and a reduction by 50% in the rate of visits to the 
emergency department. However, with a reduction by 50% in the rate of visits to primary 
care, the cost of the vaccination programme exceeded the savings among children over 6 
years of age. We found that the cost of vaccine was highly influential on the results. At an 
assumed cost of EUR 11 per dose of the vaccine, the cost of the vaccination programme 
exceeded the savings in the aggregated age group of children aged 0.5–4 years. In the 
probabilistic sensitivity analysis using Monte Carlo simulations, we obtained the following 
2.5%, 50% and 97.5% quantiles for the savings per vaccinated child (in euros): (4.1, 14.4, 
30.3) in children aged <3 years, (4.0, 12.5, 25.4) in children aged <5 years and (3.5, 10.8, 
21.9) in children aged <7 years.  
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Table 15. Results of the economic evaluation of the influenza vaccination programme in children with 
vaccine effectiveness of 80% and 60%. The effect of different vaccine effectiveness estimates on 
estimated annual outcomes prevented and health care costs saved by the vaccination programme 
versus no vaccination. All costs (EUR) are presented at the 2010 price level.  
Vaccine effectiveness 80% Vaccine effectiveness 60% 
0.5–4y 5–13y 0.5–4y 5–13y 
Influenza cases prevented, total 36 069 61 439 27 053 46 080 
Influenza and AOM 11 915 2546 8937 1910 
Influenza and pneumonia (outpatient) 1051 929 788 697 
Influenza and sinusitis 895 2762 672 2072 
Influenza, severe  737 407 553 305 
Influenza, uncomplicated  21 471 54 795 16 104 41 097 
QALYs gained 271 461 203 346 
Treatment costs saved  5 222 447 5 185 190 3 916 992 3 888 832 
Influenza and AOM 2 798 083 617 487 2 098 663 463 102 
Influenza and pneumonia (outpatient) 257 080 228 154 192 786 171 157 
Influenza and sinusitis 74 459 230 345 55 838 172 764 
Influenza, severe  583 626 257 593 437 768 193 073 
Influenza, uncomplicated  1 509 200 3 851 611 1 131 937 2 888 737 
Total direct vaccination costs -2 040 531 -3 340 136 -2 040 531 -3 340 136 
Administration costs  -1 189 345 -1 947 286 -1 189 345 -1 947 286 
Vaccine purchase*  -851 186 -1 392 850 -851 186 -1 392 850 
Health care costs saved 3 181 916 1 845 054 1 876 461 548 696 
Cost / QALY gained Cost saving Cost saving Cost saving Cost saving 
Saving (EUR) / vaccinated 12.6 3.7 7.4 1.1 
 
*Assumed vaccine price per dose EUR 2.8.  
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5.4 Coverage and frequency of organised and opportunistic Pap 
testing 
In Finland, women aged 30–60 years are invited for a test in an organised screening 
programme every 5 years. In addition, some municipalities also invite women aged 25 and/or 
65 years. Of the 446 000 Pap tests taken annually for screening purposes, 60% were taken 
outside the organised programme. The 5-year coverage and frequency of Pap testing was 
estimated based on the Helsinki metropolitan region.   
With the proportion increasing with age, 55% to 75% of women aged 30–64 years had an 
organised Pap test taken during the last 5 years. Furthermore, 51% of those attending the 
organised screening also had at least one Pap test taken outside the organised programme. 
About 60% of women in age groups 25–29 and 65–69 are invited to organised screening in 
the Helsinki metropolitan region. Therefore, the coverage of organised screening among 
women in these age groups was lower, at 33% and 46%, respectively.  
The overall coverage of Pap testing was high, with as many as 87% of women aged 25–69 
years having had at least one Pap test within or outside the organised programme during the 
last 5 years. Outside the organised programme, the 5-year coverage was highest (75%) 
among women aged 25–29 years. Most of these Pap tests were taken in public primary health 
care. Furthermore, 44% of Pap tests taken in primary health care carried out for women aged 
30 years or younger. When the organised programme starts at age 30, most of the women had 
already had a Pap test taken outside the organised programme.  
Considering all Pap tests taken within and outside the organised screening, 44% of women 
aged 25–69 years had exactly one Pap test carried out during the last 5 years. Almost 50% of 
women aged 25–54 and one-third of women aged 55–69 had two or more Pap tests taken 
during the last 5 years. The proportion of women aged 25–69 years that had two or more Pap 
tests taken during the last 5 years decreased with age from 49% to 29%.  




6.1 Main results 
This study shows the materials, methods, and results of economic evaluations of PCV7 
(PCV7-I published in article I and PCV7-II previously unpublished) and influenza (II) 
vaccination programmes and the HPV-associated cost of illness study (III, IV), all of which 
were used in the vaccine adoption decision-making process in Finland in the period 2001–
2011. The estimates produced for the disease burden and costs of HPV-related genital disease 
in women and the overall coverage, frequency and costs of Pap testing (III, IV) were further 
used as data in the HPV transmission and progression model and in the economic evaluations 
of the HPV vaccination programme and the screening for cervical cancer (217-219).  
The infant PCV7 vaccination programme (excluding indirect herd effects) was not deemed 
cost-effective by the decision-makers at the anticipated vaccine price (PCV7-I). In the 
economic re-evaluation (PCV7-II), the indirect herd effects of the vaccination programme 
were included in older age groups, in which case the decision-makers found the infant PCV7 
vaccination programme likely to be cost-effective on the basis of an assumed threshold of 
EUR 25 000 per QALY. Furthermore, the change from the 4- to 3-dose programme lowered 
the anticipated vaccination costs and improved the cost-effectiveness in the re-evaluation.  
The influenza vaccination programme for healthy children was found to be cost saving from 
the health care provider perspective even though the indirect herd effects and influenza-
associated deaths were excluded. The vaccination programme was estimated to save annually 
EUR 7.6 per vaccinated child aged 0.5–4 years when the assumed vaccine efficacy was 60%.  
In Finland, there is a considerable annual disease burden of HPV-related genital disease in 
the female population. Most of it is detected by means of the 446 000 annual screening tests, 
55% of which are carried out as opportunistic tests. It is noteworthy that the opportunistic 
tests account for 71% of the total of EUR 22.4 million screening costs (IV). Considering all 
tests taken both within and outside the organised programme, the 5-year coverage of Pap 
testing in Finland was 87% among women aged 25–69 years. Further diagnostics, 
management, and treatment of HPV-related genital disease resulted in an additional cost of 
EUR 22.3 million, of which the costs of less severe HPV-related disease manifestations were 
EUR 15.5 million (III).  
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6.2 Strengths and limitations  
The high quality data sources is an evident strength of these studies. The incidences of AOM 
were obtained from a well-documented vaccine efficacy trial covering more than 50% of the 
birth cohort in the study area (44) and data on the frequency of Pap tests from comprehensive 
regional primary health care. CAP cared for solely in primary health care was the only 
disease category, the burden of which was estimated using several data sources. Except for 
the aforementioned outcomes, all other incidences of pneumococcal- and HPV-related 
disease were estimated from individual-level nationwide population-based register data. In 
the HPV dataset, the data sources were individually linkable even between the registers. The 
incidences of influenza-related outcomes were obtained from an epidemiological cohort study 
of laboratory-confirmed respiratory infections in children (108). 
The heath-care-resource use due to disease outcomes was, with one exception (AOM), 
estimated from individual-level register data in the economic re-evaluation of the PCV7 
vaccination programme (PCV7-II) and in the cost-of-illness study of HPV-related genital 
disease in women (III, IV). In the first economic evaluation of the PCV7 programme (PCV7-
I) and in the economic evaluation of the influenza vaccination programme (II), the health care 
resource use was estimated from epidemiological studies, the regional hospital register, and 
according to expert opinion.  
The lower burden of pneumococcal-related disease among children aged 0 to 4 years in the 
economic re-evaluation of the PCV7 programme (PCV7-II) compared to the first study 
(PCV7-I) is explained by a lower pneumonia incidence (10.3 per 1000), which was only one 
third of the incidence used in the first study (28.5 per 1000). This was mainly due to the 
differences in case definitions of pneumonia between studies: all-cause pneumonia in the first 
study (PCV7-I) and potentially pneumococcal pneumonia in the re-evaluation (PCV7-II). In 
the first study (PCV7-I), the incidence of pneumonia was obtained from a prospective 
regional epidemiological study conducted in 1981–1982 (34, 191). In the re-evaluation, the 
incidence of inpatient and outpatient pneumonia in secondary health care was estimated from 
individual-level register data (Hospital Discharge Register, 2001–2006) in which the 
pneumonia cases were retrieved with ICD-10 codes for pneumococcal (J13) or unspecified 
(J15.9, J18.1, J18.8 and J18.9) pneumonia. The total incidence of outpatient pneumonia was 
derived from the inpatient pneumonia incidence by assuming the proportions of inpatient and 
outpatient cases to be the same as in the Jokinen study (191). In the re-evaluation, the 
incidence of potentially pneumococcal pneumonia may have been underestimated, since 
pneumonia, like many other childhood illnesses, was most likely treated more often in 
inpatient care in the 1980s than in the 2000s (220). Compared to the first study (PCV7-I), the 
lower incidence of pneumonia in addition to the exclusion of the adenotomies from the 
analysis in the PCV7 re-evaluation (PCV7-II) resulted in markedly lower estimated health 
care costs without vaccinations.   
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In the PCV7 re-evaluation, in addition to the underestimated pneumonia incidence, the 
impact of the vaccination programme on pneumonia is likely to have been underestimated, 
since a low vaccine efficacy estimate of 4.3% (55) for all-cause pneumonia was applied to a 
more specific outcome of potentially pneumococcal pneumonia. In fact, PCV10 later showed 
an effectiveness of 27% against any hospital-diagnosed pneumonia, having an incidence as 
high as 13.3 per 1 000 person-years in infants followed on average for up to 27 months of age 
(35). However, in the vaccinated effects scenario (PCV7-II), this has a minor impact on the 
results. Even if the same pneumonia incidence and estimate for vaccine efficacy as in the first 
study (PCV7-I) were used, the cost per QALY gained would only decrease from EUR 83 759 
to EUR 78 071 in the re-evaluation. In addition, we underestimated the costs of neurologic 
sequelae after meningitis by including only the first-year costs in the analysis.    
In both economic evaluations of the PCV7 programme the direct vaccine efficacy estimates 
against IPD were not adjusted with the serotypes circulating in Finland. We used directly the 
vaccine efficacy estimates from the Northern Californian vaccine efficacy study, where the 
PCV7 serotype coverage of IPD in the control group was 89% (54). At the time the analyses 
were conducted, the serotyping results were not linked with the National Infectious Disease 
Register notifications and the estimated serotype distribution in Finland was expected to be 
imprecise. In Finland the National Infectious Disease Register notifications and the 
serotyping results have been linkable using the unique personal identity code only since 2004. 
Furthermore, it could be seen that adjusting VE with the estimated imprecise IPD serotype 
distribution was not influential on the results. Retrospectively it is possible to compare the 
data available at the time the analyses were conducted and the pre-vaccination period data. In 
Finland (1995–2002) the estimated PCV7 serotype coverage of IPD was 57%, 76% and 71% 
in children aged <1, 1, and 2–4 years, respectively (193). In the pre-vaccination period 
(2006–2008) in Finland, the estimated PCV7 serotype coverage of IPD was 77% in children 
aged <2 and 83% in children aged 2–4 years (National Infectious Diseases Register). The 
data in 2006–2008 has been validated in the FinIP trial (56). Although the vaccine serotype 
coverage and thus the direct vaccine effectiveness against IPD are likely to be overestimates 
in both economic evaluations, the influence on the results was minor. In the re-evaluation 
(PCV7-II), the proportion of estimated treatment costs saved due to IPD in total health care 
costs was 3%, and the proportion of QALYs gained due to IPD in total QALYs gained was 
31%. Adjusting the direct effect according to the pre-vaccination serotype distribution in 
Finland would increase the cost per QALY gained from EUR 83 759 to EUR 87 209, when 
only the direct effect of the programme was taken into account. 
In the indirect effects scenarios (PCV7-II), in addition to the direct effect we assumed the 
PCV7 vaccination programme to reduce 20% of the IPD cases (scenario A) or 20% of the 
IPD and 4% of the pneumonia cases treated in secondary health care (scenario B) in the 
unvaccinated population aged ≥5 years. Retrospectively, the assumed indirect herd effect was 
an overestimate in both scenarios. The impact of the PCV10 vaccination programme that 
started in September 2010 in Finland was estimated by comparing the incidence of IPD cases 
in pre- (2006–2008) and post-vaccination (2012–2014) periods. The incidence of IPD cases 
decreased in the unvaccinated population aged 5–49, aged 50–64 and aged ≥65 years by 20%, 
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5.0% and 5.2%, respectively (221). In an observational study comparing hospitalisation rates 
for pneumonia in Finland before (2004–2010) and after (2011–2014) the PCV7 programme 
was introduced, the incidence rates of hospital-treated pneumonia declined in the population 
aged 18–49, aged 50–64 and aged ≥65 years by 11.4%, 20.9% and 7.29%, respectively (222). 
However, these results may also be affected by other factors, such as influenza vaccinations, 
potential variation of pneumonia hospitalizations due to other pathogens, or changing coding 
practices. In other European countries, there is also evidence of serotype replacement that is 
resulting in a lower level of indirect protection. Assuming the PCV7 vaccination programme 
reduces 20% of the IPD cases (scenario A), this reduces the cost per QALY gained from 
EUR 83 759 to EUR 20 558. The reduction is mainly due to the incidence and case fatality 
ratio of IPD, both of which increase with age. If the incidence of IPD cases decreased in the 
unvaccinated population by only 5%, the cost per QALY gained would be EUR 49 600 at the 
vaccine prices of that time. However, the PCV10 vaccine was purchased for the NVP with a 
lower price than foreseen in the economic evaluations of PCV7 (PCV7-I, PCV7-II). In 
addition, a PCV10 effectiveness study has shown that the vaccination programme also 
reduced the incidence of clinically suspected non-laboratory-confirmed IPD in the vaccinated 
(56). Therefore, the PCV10 vaccination programme is most probably cost-saving from the 
health care provider perspective even at the lower level of the indirect herd effect.  
Given the seasonal variation in influenza prevalence and the match between the vaccine and 
circulating subtypes of the virus, the influenza vaccine effectiveness varies from one 
influenza season to another (118, 122). In the base-case of the economic evaluation of 
influenza vaccination programme in children, we assumed the effectiveness of TIV to be 80% 
(II), which may be an overestimate for some of the seasons (122). Furthermore, the 
vaccination programme was cost-saving from the health care provider perspective even with 
a 60% vaccine efficacy. However, in some seasons, an even lower vaccine efficacy with a 
poor vaccine match with circulating viruses is possible.   
In the economic evaluation of the influenza vaccination programme, we unrealistically 
assumed 100% vaccination coverage. In reality the coverage of the influenza vaccination 
programme in children <3 years of age is considerably lower. In the 2015–2016 season it was 
24%. Thus, the potential total savings from the vaccination programme when assuming 100% 
vaccine coverage do not represent realistic estimates of the impact of the programme on the 
disease burden and costs. However, the expected cost-savings per vaccinated child is valid 
information for decision-making. In the economic evaluation, we made assumptions that 
were unfavourable for the vaccination programme: excluding influenza-associated deaths 
from the analysis and ignoring the herd effect. However, the exclusions did not jeopardize the 
decision-making, since even with these unfavourable assumptions, the vaccination 
programme was found to be cost-saving. We found that the cost of the vaccine was highly 
influential on the results.    
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This is the first study to reveal that the low cervical cancer incidence in Finland is not only 
due to the performance of organised screening but also due to extensive and expensive Pap 
testing occurring outside the organised screening programme (III, IV). Moreover, for the first 
time we showed the incidence and costs of the less severe HPV-related disease 
manifestations detected in Finland.  
The estimates on how the disease outcomes affect health-related quality of life were obtained 
from the literature. It is noteworthy that because the data were scarce, QALY weights 
associated with disease outcomes were not age-dependent. This is an inaccurate assumption 
since the health-related quality of life is known to be age-dependent (203). However, the 
impact on QALYs gained is negligible in the economic evaluations of vaccination 
programmes in children, where only direct protection for a limited time is assumed. This was 
the case in the first economic evaluation of PCV7 (PCV7-I), in the vaccinated effects 
scenario in the re-evaluation (PCV7-II), and in the economic evaluation of influenza 
programme in children (II). Yet in the re-evaluation of the PCV7 vaccination programme, the 
QALYs gained in the indirect effects scenarios may be overestimated. However, this had a 
minor impact on the results, since the QALYs gained consisted mostly of life-years gained, 
which can been seen in the cost per QALY gained (EUR 20 558) and in the life-years gained 
(EUR 25 839), which were close to each other. It is noteworthy, that although the average 
health-related quality of life estimate (unrelated to a specific disease) declines with increasing 
age, the life years gained was estimated assuming that all life-years would have been lived in 
perfect health.  
Despite EQ-5D and 15D being known to lead to different estimates of QALYs gained (203), 
we used estimates of these different instruments in assessing the health-related quality of life 
of the diseases. The 15D estimates were used for hearing defect related to pneumococcal 
meningitis and HPV-related cervical abnormalities (e.g. CIN and minor cytological 
abnormalities). Since QALYs gained related to pneumococcal meningitis was less than 1% of 
the total QALYs gained, the impact of using different instruments on the cost-effectiveness of 
the PCV7 vaccination programme was negligible. The 15D estimates (205) for HPV-related 
cervical abnormalities were somewhat lower than, for example, the trade-off (223) or 
EuroQol (224) estimates used in other studies. Nevertheless, the HPV vaccination 
programme has been estimated to be cost-saving in Finland even with the lower 15D 
estimates (219).   
In order to be able to compare the costs of different diseases, all costs are presented in euros 
at the 2010 price level. Thus, the costs in the economic evaluations of the PCV7 and 
influenza vaccination programmes were transformed from values given in the original 
publications (I, II) or study (PCV7-II) according to the appropriate price indices. During the 
period between the time the economic evaluations of PCV7 were conducted (PCV7-I, PCV7-
II) and 2010, the cost of the vaccine and health care costs in general changed in opposite 
directions: the cost of the vaccine has fallen and health care costs have risen. Our intention in 
this study was to summarise the results used in the decision-making at the time the vaccines 
were considered for inclusion in the NVP. Therefore, the cost of PCV7 was transformed with 
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the same consumer price index as the rest of the health care costs. If we had used the real cost 
of the vaccine in 2010, we would have altered the results and conclusions of the economic 
evaluations, since the vaccine price was an influential variable when estimating the cost-
effectiveness of the vaccination programmes.  
Most of the unit cost estimates in secondary health care (inpatient hospitalisation, outpatient 
visit) were estimated separately for specific disease-related outcomes (e. g. pneumococcal 
meningitis or cervical cancer) from individual-level cost accounting data from the Hospital 
District of Helsinki and Uusimaa. The secondary health care data collected in the studies 
included the cost accounting data for this single hospital district. In the first economic 
evaluation of the PCV7 programme, the unit cost estimates in secondary health care were 
partly obtained from the widely used National pricelist for unit costs of health care in Finland 
(197-199). In this pricelist, the unit costs are estimated from individual-level cost accounting 
data from 20 Hospital Districts in Finland for broader outcomes such as outpatient visit by 
speciality or inpatient hospitalisation by Diagnostic Related Groups classification system. 
The national pricelist for unit costs of health care in Finland is published by THL and updated 
every few years. The difference in the unit cost estimates of secondary health care in 
economic evaluations of the PCV7 programme (PCV7-I, PCV7-II) was due to inflation and 
these different sources for the estimates.  
6.3 Comparison with other studies 
In Europe, PCV7 came to the market in 2001. In the first economic evaluations, the 
vaccination programme was not reported to be acceptably cost-effective from the health care 
provider perspective at the vaccine prices of that time without taking into account the 
potential herd effects (81, 94, 96, 100). This finding is in line with our results (PCV7-I, 
PCV7-II).   
There are many studies in which trivalent inactivated influenza vaccinations were reported to 
be cost-saving from the societal perspective (137-140). In addition to this study, at least 
Esposito and colleagues (134) have reported the influenza vaccinations to be cost-saving also 
from the health care payer perspective. In our study the cost for vaccine per dose (wholesale 
price) was considerably lower compared to other studies. Importantly, vaccine price for 
influenza vaccines used in the national programme was the most accurate variable used in our 
analysis.  
In Finland, children aged 0 to 4 years experienced 250 000 episodes annually of all-cause 
otitis media, of which almost 16 000 were influenza-related (I, II). Otitis media was a driving 
factor when estimating the cost-effectiveness of the PCV7 programme (direct effects 
scenario) and the influenza vaccination programme in children. In fact, we estimated that 
almost 10 000 episodes of otitis media could potentially be prevented with either vaccination 
programme.   
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Finland appears to have the highest reported 5-year coverage of Pap testing among women 
aged 25–64 years in Europe when taking into account all Pap-tests within or outside the 
organised programme (166). However, countries starting the screening programme at the age 
of 25 or earlier and having a 3-year interval, might end up having a fairly similar Pap testing 
frequency to Finland.  
Although the overall cervical cancer incidence is very low in Finland, the incidence among 
women aged 20 to 39 years has increased during the last 15 years (167, 225). The new 
finding of this study was the high Pap testing coverage among young women. Furthermore, 
the extensive Pap testing easily leads to unnecessary treatments. Preventing cervical cancer 
among young women by means of screening is difficult, since the HPV infection and 
precancerous lesions, which are highly likely to regress spontaneously, are most prevalent in 
women in their 20s and 30s. Therefore, among young women, HPV vaccinations that have 
been shown to reduce a considerable part of the HPV burden (169, 226) are the primary 
intervention in preventing cervical cancer and precancer.  
In Finland, the National Advisory Committee on Vaccinations (KRAR) makes national 
recommendations on immunization policy. In many countries, there is an equivalent 
independent expert group, often called the national immunisation technical advisory group 
(NITAG). No less than 26 European countries report having a NITAG (227). The Finnish 
KRAR was established in 2001. The UK was among the first countries that established a 
NITAG: The British Joint Committee on Vaccination and Immunisation was established in 
1963 (228). Of the European countries, 20 report to carry out a systematic vaccination 
decision-making process in which multiple criteria are considered (227). Among other, these 
criteria include estimating the epidemiology of vaccine preventable disease, the efficacy and 
safety of the vaccine, the effectiveness and cost-effectiveness of the vaccination programme, 
and the programme implementation. These criteria include also the criteria given by KRAR, 
according to which new vaccines are evaluated in Finland.   
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6.4 Implications for policymaking  
The burden of disease and health care costs to providers always reflect the national health 
care system at that time. This could be seen in the detected cases of cervical cancer or CIN, 
which depend mainly on current Pap testing practices. At present, 60% of Pap tests are 
carried out outside the organised programme, from which 89% of cervical cancer cases and 
80% of CIN cases are detected in Finland (229). Thus, the successful reduction in cervical 
cancer incidence and mortality is due to tests taken both within and outside the organised 
screening. The opportunistic Pap testing both substitutes and overlaps with the tests taken in 
the organised programme. Overlapping tests stem from the lack of coordination between 
organised and opportunistic Pap testing and results in over-management of reversible lesions. 
In order to be able to coordinate organised and opportunistic Pap testing, it is essential to 
establish a nationwide Pap test register. Furthermore, such a register is necessary for effective 
and cost-effective secondary prevention of cervical cancer, which will be needed in both 
unvaccinated and vaccinated populations.   
The high Pap testing coverage among young women is a result of their repeated contacts with 
several health care providers. In addition to organised screening, women aged <39 years are 
tested in public primary, student, and private health care. It is important not to lose the high 
coverage when trying to achieve reductions in overlapping Pap testing. This is one additional 
reason why it is essential to establish a nationwide Pap test register that is accessible to all 
health care providers.  
In Finland, the economic evaluation of the vaccination programme has been part of the 
decision-making process since 2001. After 2003 there are five vaccinations that have been 
considered for the Finnish NVP and for which an economic evaluation has been conducted. 
Vaccinations of all children aged 6–36 months with influenza vaccine were estimated to be 
cost-saving (II) and the vaccine was accepted into the NVP in 2007. Infant’s rotavirus and 
pneumococcal vaccinations were accepted into the NVP in 2008 and 2010 with a cost per 
QALY gained of EUR 25 000 (230, 231) and EUR 20 490 (232), respectively. Vaccinations 
of all girls aged 11–13 years with HPV vaccine was estimated to be cost-saving (219) and 
was accepted into the NVP in 2013. Varicella vaccinations were concluded to be acceptably 
cost-effective with a cost per QALY gained of EUR 15 000 (233). Vaccinations were 
included in the Government's budget proposal in August 2016 and they will start in 2017. All 
these results of economic evaluations are from the health care provider perspective.  
In Finland, the prices at which vaccines are finally purchased for the NVP are not known in 
advance. However, the prices are as a rule below the pharmacy price due to the centralised 
purchasing system and a competitive tendering process. The prices at which vaccines against 
rotavirus, pneumococcus and HPV were eventually purchased for the NVP were lower than 
the anticipated price that was used in the economic evaluations. Actually, both rotavirus and 
pneumococcal vaccinations are expected to be cost-saving from the health care provider 
perspective with the post-vaccination effectiveness (72, 234) and actualised vaccine prices.  
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6.5 Unanswered questions and directions for the future 
The studies presented were all conducted for the decision-making process for adopting 
potential new vaccines in the NVP. However, an assessment only prior to vaccine 
introduction is not sufficient. Continuous assessment of both post-implementation 
effectiveness and cost-effectiveness of the publicly funded vaccination programmes is 
equally important (235). In retrospective economic evaluations, the sources of uncertainty 
can be reduced and therefore the estimates for cost-effectiveness might be more reliable. The 
impact of the vaccination programme can be confirmed or challenged by the post-
implementation surveillance of the direct and indirect herd effects of the programme and 
vaccination coverage. In addition, the price at which the vaccine was actually purchased for 
the NVP is known. For example, the current price for PCV10 is considerably lower than the 
assumed price of the PCV7 in the pre-implementation economic evaluations. When new 
vaccine products arrive in the market the up-to-date detailed data on the burden of disease are 
important in comparing the products. It is also possible that there is a need to reassess the 
target groups of the vaccinations. An invitation to tender is put out every 2–3 years for each 
vaccine. Economic evaluations need to be updated also for these competitive tendering 
processes, where the economic evaluation is used in setting evaluation criteria for tender 
specification for the vaccine.  
In Finland, decision-makers have not specified an explicit threshold for cost-effectiveness, 
below which an intervention or programme would automatically be accepted and lead to 
funding. However, an explicit range of cost-effectiveness threshold values would improve the 
transparency in decision-making and would therefore be highly advisable. The process of 
adopting a new vaccine into the national vaccination programme provides an established 
roadmap for decision-making in health care. In this process, an economic evaluation serves as 
an indispensable node.    
 




1. Since resources are scarce, new health care interventions need to be carefully 
considered. In Finland, the development of the national vaccination programme 
(NVP) is based on four criteria: expected public health benefit, safety of a vaccine for 
an individual, safety of the programme at the population level, and its cost-
effectiveness. It is not self-evident that introducing a new vaccine into the NVP is 
making the most of our common resources.  
2. Economic evaluations are needed to support the decision-making process so that 
decision-makers are informed and able to choose from among potential alternatives. 
Likewise, economic evaluations are needed for a competitive tendering process when 
purchasing vaccines for the NVP. In Finland, economic evaluations of vaccination 
programmes have been part of the decision-making process since 2001. Assessing an 
explicit threshold range for cost-effectiveness, below which an intervention would be 
accepted and lead to funding would improve the transparency in decision-making and 
therefore would be highly advisable.  
3. The PCV7 vaccination programme was found to be cost-effective when taking into 
account the direct and indirect herd effects of the vaccination programme. However, 
more recent data on observed indirect effect suggests that expected herd effects have 
not been observed, unlike the direct effects, which appear better than expected.   
4.  The influenza vaccination programme of children aged 6 months to 13 years was 
estimated to be cost-saving from the health care provider perspective with the 60% 
vaccine efficacy. The price of vaccine, the influenza incidence and the vaccine 
efficacy were highly influential on the results of the cost-effectiveness analysis. 
However, there is considerable seasonal variability in influenza epidemics and in the 
match between the vaccine and circulating subtypes of the virus.  
5. There is a considerable disease burden of HPV-related genital disease in the female 
population in Finland. The detection of cervical cancer or CIN is highly dependent on 
the current Pap testing practices. At present, 60% of Pap tests are carried out outside 
the organised programme, from which 89% of cervical cancer cases and 80% of CIN 
cases are detected.  
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6. The 5-year coverage of Pap testing in Finland is very high (87%) when tests taken 
both within and outside the organised programme are taken into account. 
Opportunistic Pap testing both substitutes and overlaps with tests carried out in the 
organised programme. Overlapping tests stem from a lack of coordination between 
organised and opportunistic Pap testing and result in over-management of reversible 
lesions. It is critical not to lose the high coverage when trying to achieve reductions in 
overlapping Pap testing. In order to be able to coordinate the organised and 
opportunistic Pap testing and develop a cost-effective strategy for the secondary 
prevention of cervical cancer, it is essential to establish a nationwide Pap test register.  
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